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Background: Chronic inflammation is linked to the onset of diabetes, heart disease, liver 
disease, neurological diseases and even certain cancers. In the brain, inflammation activates and 
promotes recruitment of microglia (i.e. reactive microgliosis) and is implicated in the 
pathogenesis of a number of neurodegenerative diseases. Inflammatory stimuli can cause 
glucose/insulin intolerance, disrupt liver lipid transport, metabolism and catabolism leading to 
pre-mature liver failure and cancer.  A standardized Pomegranate extract (PE) and Maple Syrup 
Extract (MSX) could be a source of beneficial phytonutrients capable of mitigating these 
inflammatory processes.                        
Methods: A pilot scale diet-induced obesity study with Male C57BL/6 mice with or without PE or 
MSX for 12 weeks was used to probe if PE or MSX could prevent inflammation within the 
hippocampus. A larger C57BL/6 mouse modeling a typical western diet was used to further 
evaluate MSX for its ability to modulate inflammation and metabolic syndrome progression. 
Finally, a human macrophage study modeling systemic inflammation and a co-culture system of 
murine microglia and human neurons modeling the microenvironment within the brain were 
used to explore anti-inflammatory effects of PE metabolites (urolithins) and MSX.             
Results and Conclusions: Mice fed a HFD for 12 weeks showed elevated expression of both pro 
and anti-inflammatory cytokine/growth factors and neurodegenerative associated genes in 
hippocampal tissues. PE in HFD reduced the gene expression of IL-1α, IL-1β, IL-7, IL-11, TNFα, 
MAPT, APP, GSK3β, and LEPR. MSX in HFD feed decreased the gene expression of IL-7, IL-11, IL-
19, TNFα, IFNα, CD40L, CD70, NFE2L2, SOD1, ITGAM, and LEPR. In a western diet model, MSX 
increased liver lipids, decreased white adipose tissue weight and serum levels of IL-6. In human 
macrophages, MSX reduced cytokine release. In a co-culture neuroinflammation model, 
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JUSTIFICATION OF RESEARCH 
To date, chronic inflammation during the course of an individual’s lifetime is cited as a 
significant causality to a number of diseases and disorders. Such diseases  include diabetes, 
heart disease, liver disease,  neurological diseases and even neoplasias of the liver, prostate, 
brain (Glioma/Glioblastoma)  and colon 1–4. Moreover, this inflammation stems from not just 
lifestyle choices (poor eating habits, smoking, alcohol consumption etc.) but from environmental 
toxicants (e.g. pollutants, pesticides, contaminants, radiation, pathogens etc.). Latter factors 
lead to the generation of free radicals and cause the malfunction of key cellular process proteins 
which are involved in cell repair and survival5,6. 
Inflammation localized to the brain however, has been extensively studied and 
positively linked to the pathogenesis of Alzheimer’s disease, Parkinson’s disease, Amyotrophic 
Lateral Sclerosis, and Gliomas 2,7–10.  Neuroinflammation is a primary driver of Alzheimer’s 
disease11–13. One major hypothesis involves an axis between microglia (the resident 
macrophages of the brain) and neurons. The ability to mitigate the effects of damage associated 
molecules (e.g. Beta Amyloid, Advanced Glycation End products (AGEs), and ATP ) and pathogen 
associated molecules (e.g. Lipopolysaccharide(LPS) , Flagellin, CpG Bacterial DNA, and Viral 
Envelope Particles) are regulated by microglia13,14. 
Macrophages and microglia are able to recognize these molecules by way of Toll-Like 
receptors (TLRs) and by Nod-Like Receptors (NLRs).  Toll-Like receptors are multi-subunit trans-
membrane proteins and will respond to specific pathogenic or damage molecule patterns by 
binding to one of the aforementioned ligands and create  an intracellular signal triggering an 
intracellular cascade (increasing mitochondrial respiration, elevating arginase expression etc.) 





Microglia mediated neuronal cell death is the result of an over stimulation of microglia 
(aka reactive microgliosis) which will produce a multitude of pro-inflammatory stimuli including 
but not limited to , reactive metabolites  such as Nitric Oxide (NO),  Reactive Oxide Species (ROS)  
Prostaglandins (i.e. PGE2),  Th1 Cytokines (Tumor Necrosis Factor Alpha (TNFα) and Interferon 
Gamma  (IFNγ) ) , Interleukins (IL-1β, IL-6, IL-8, etc.) and other pro-inflammatory molecules16–
18.These pro-inflammatory molecules signal to neighboring macrophages to be in an aggressive 
and consequently pro-inflammatory state  thus perpetuating the secretion of inflammatory 
signaling molecules. 
The constant activation of microglia is a major cause of both the hyperphosphorylation 
of microtubule associated protein tau (MAPT) and  the cleavage of APPβ to neuro-toxic Beta 
Amyloid  19,20. This finding supports that AD is a progressive, multimodal disease state that 
includes an induction of Aβ by inflammatory means, peptide deposition within the brain (which 
occurs 10-20 years before symptoms are presented), an increase in reactive 
species/inflammatory mediators, neuron cell death and a down-regulation of key Aβ binding 
clearance proteins on macrophages and the epithelia on the Blood Brain Barrier (BBB)18,21–23.  
Diet-induced obesity caused by sedentary behavior and poor diet, have been associated 
with metabolic syndromes such as type II diabetes mellitus (T2DM), nonalcoholic fatty liver 
disease (NAFLD) and even nonalcoholic steatohepatitis (NASH)24–27. The western diet is 
characterized to be high in saturated fats and sugars (sucrose/fructose)  and  has been shown in 





This dysbiosis shifts the secondary metabolism of these microbes to produce harmful 
pro-inflammatory metabolites. These inflammatory metabolites not only alter localized innate 
immune response within the gut, but alter the integrity of the gut leading to what is regarded as 
“leaky-gut syndrome”30. The act of the gut lining being compromised, allows for these harmful 
metabolites and endotoxins (lipopolysaccharides (LPS)) to permeate through the large intestine 
into blood stream. This excess of pro-inflammatory stimuli causes a low-grade constant 
activation and differentiation of peripheral monocytes and macrophages. Therefore, this 
persistent release not only causes tissue damage within the gut, liver and cardiovascular system 
but also reduces sensitivity to insulin (and subsequently the tolerance to glucose), increases 
formation of sclerotic plaques within blood vessels, initiates fibrosis and cirrhosis in the liver and 
even alters the functionality of adipocytes leading to dyslipidemia (e.g. hyperlipidemia)31,32. 
By modulating inflammation and the upstream targets to these diseases, this may serve 
as an alternative to simply “treating” to alleviate symptoms and only delay inevitable and 
irreversible patient outcomes. Therefore, prevention of these diseases by lowering 
inflammation and disease associated enzymes/proteins with a cost effective, low toxicity, and 






One potential source of these chemical entities could come from our diet in the form of 
gut microbe metabolites (GMMs). More specifically, metabolites derived from foods rich in 
polyphenols, such as ellagitannins, lignans, phytoestrogens, flavonoids, and phenolic acids 40. 
Numerous studies have already shown the importance of the metabolome and their role in 
modulating several disease states41–44. In other words, the metabolism and otherwise 
biotransformation of large parent compounds by commensal bacteria into biologically active 
small molecule constituents has a profound impact on the maintenance of the host organism’s 
overall health. 
These metabolites are generated due to the diverse populations of bacteria that are 
harbored within the gut. Of these metabolites, is a group of small, rigid, planar compounds 
classified as urolithins45,46. Urolithins are the metabolites derived from gut microflora 
metabolism of ellagitannins, which are primarily sourced from oak aged beverages (e.g. wine, 
port, sherry, or whisky), raspberries, blackberries, walnuts, and pomegranate47–49.  
Over the years, urolithins have gained appreciable amount of attention due to their 
small molecular weight (passive absorption into cells and other barriers),  generally low toxicity 
systemically, and diverse functions as an anti-cancer and anti-inflammatory agent46,50–52.   
Furthermore, the biogeneration of urolithins are variable from individual to individual. The 
bacterial species responsible for the majority of this biotransformation is Gordonibacter 
urolithinfaciens  and its activity/rate of biogenesis is dependent on the bacterial host’s diet, 





The other potential source of GMMs is from maple syrup, and more specifically, a 
proprietary polyphenol-enriched, food grade extract designated as MSX. Maple syrup is a widely 
used and accessible sweetener derived from the boiling of sap from Acer saccharum L. (Sugar 
Maple)56. Recently, a food grade, polyphenol-enriched extract has been developed from 
polyphenol-rich fractions of maple syrup.  This extract has been studied for its modulation of 
glucose consumption in liver cells (HepG2), abrogation of LPS mediated inflammation in murine 
macrophages (RAW 264.7) and safety in rats at doses up to 1000 mg/kg /day 57. 
 Other maple syrup extracts have been produced in other labs but MSX is unique in its 
composition and method of preparation 58,59. MSX contains over 60 phytochemicals from several 
polyphenol classes such as phenolic acids, coumarins, lignans, and stilbenes. One such 
polyphenolic class, lignans ( e.g. Secoisolariciresinol-diglucoside (SDG)),  exhibit anti-
inflammatory and anti-cancer activity60,61. These lignans, while also regarded as phytoestrogens 
based on their structural resemblance to 17β-Estradiol, are able to be transformed by gut 
microbes to enterolignans such as Secoisolariciresinol (SECO), Enterodiol (ED), and 
Enterolactone (EL)62,63.These enterolignans, while also found in flaxseed (Linum usitatissimum L.) 
are able to pass the gut membrane and enter systemic circulation64,65.  Interestingly, of the 
metabolites, EL (one of the most biologically active  but least abundant metabolite) has been 
found to enter the brain66,67.  Therefore, MSX could serve as a source of the parent molecules 
needed to potentiate effects of inflammation. 
Herein, this body of work will highlight some of the methods used to obtain data to 
further guide this exploration of PE and MSX for their role in mitigating inflammation mediated 
neurodegeneration in vitro as well as their role in modifying outcomes associated with 
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Background: Poor diet can promote obesity and gut microbe dysbiosis, which increases 
circulating endotoxin levels. In the brain, this inflammatory stimulus activates and promotes 
recruitment of microglia leading to reactive microgliosis and implicated in the pathogenesis of a 
number of neurodegenerative diseases. Pomegranate extract (PE) could be a potential source of 
beneficial phytonutrients capable of mitigating these inflammatory processes from occurring. 
Methods: Male C57BL/6 mice fed either a high fat diet (45% kcal from fat) or a standard grain 
free rodent diet (10% kcal from fat) with or without PE at a dose of 1% w/w for 12 weeks 
producing an a diet-induced obesity phenotype. Mice were sacrificed following 12 weeks and 
whole hippocampi were excised for multiplexed gene expression analysis of inflammatory and 
neurodegenerative disease associated genes. 
Results: Mice fed a HFD for 12 weeks exhibited elevated expression of both pro- and anti-
inflammatory cytokine/growth factors and neurodegenerative associated genes in the 
hippocampus. In HFD mice, PE supplementation allowed for a significant reduction in the gene 
expression of a number of key pro-inflammatory cytokines such as IL-1α, IL-1β, IL-7, IL-11, TNFα, 
MAPT, APP, GSK3β, and LEPR. 
Conclusions: In the hippocampus, immune cell recruitment and differentiation for tissue repair, 
leptin signaling and neurofibril processing via the MAPT-GSK3β-APP axis are significantly 








Poor diet has been linked to the generation of low grade inflammation systemically 1. 
Dietary factors also influence the onset of Type II Diabetes Mellitus (T2DM), Cardiovascular 
Disease, Non Alcoholic Steatohepatitis (NASH), Non Alcoholic Fatty Liver Disease (NAFLD) and 
numerous forms of neoplasias 2.  Gut microbes are tasked with not only aiding in nutrient 
extraction, immune cell programming, and maintaining intestinal barrier integrity3. Specific 
pathogenic strains may be promoted through poor diet and thus are a major source of pro-
inflammatory molecules such as lipopolysaccharide (LPS)4,5. LPS, a pathogen associated 
molecular pattern (PAMP), is recognized by  Toll Like Receptors of macrophages which signal for 
recruitment and activation of additional lymphocytes and leukocytes 6,7. LPS has been found in 
the plasma of both obese individuals and in patients diagnosed with neurodegenerative diseases 
(e.g.  Alzheimer’s disease (AD), Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis 
(ALS))8–10. These diseases represent a significant portion of the global economic burden 
associated with an aging population11. The progressive loss in neuron function and viability is 
associated with aging and neuroinflammation12. Neuroinflammation, which is largely governed 
by the resident immune cells of the brain, microglia 13 has been associated with the etiology of 
AD and PD  in rodents and patients   14,15. 
One commonly observed site of this neuroinflammatory process is the hippocampus.  
The hippocampus is responsible for maintaining basic cognitive function and memory and is one 
of the first regions to be affected by this inflammatory insult 16,17. The hippocampus is also a 





By feeding mice a diet rich in saturated fats , this diet promotes features exemplified by 
obese individuals consuming a  “western” diet  as seen in North America and Europe 20.  
Treatments for these diet associated disorders range from lipid/cholesterol reducers 
Statins (atorvastatin, simvastatin), insulin sensitizers such as metformin and thiazolidinediones 
(e.g. rosiglitazone), alpha-glucosidase inhibitors, Fibrates, Non-steroidal Anti Inflammatory 
Drugs (NSAIDs) and cholinesterase Inhibitors 21–27. These therapies, which are linked to a number 
of undesirable side effects, have been substituted for less detrimental  forms of medicine such 
as  diet restrictions, bariatric surgery, and exercise21,22. Natural products have also been 
considered for patients with metabolic syndrome (MetS) on the basis of safety and cost 28–30. 
While numerous in vitro, in vivo and human clinical studies with natural product usage in MetS 
diseases such as NASH have been published, understanding of the underlying molecular 
mechanisms of natural products and traditional herbal medicines (e.g. Ayurveda and Traditional 
Chinese medicine) in the brain are less defined. Polyphenols, represent a significant portion of 
the natural products commonly studied in age-related disease states and cancer31–34.  
One source of these natural products is derived from pomegranate (Punica granatum). 
A commercially available pomegranate extract (PE) which is standardized to its major chemical 
constituent, Punicalagin (PA),  has also been studied for its anti-bacterial, anti-inflammatory and 
anti-diabetic properties35–38. PA and its metabolite, ellagic acid (EA), are known to be 
metabolized by specific gut microbes and transformed to a class of significantly studied and 





The anti-inflammatory capacity and mechanisms of these constituents have also been 
investigated using an in vitro model of neurodegeneration with murine microglia and human 
neurons 41,42.  Our group has previously measured the ability of PE to combat the effects of AD in 
an Beta-amyloid transgenic mouse model 43. Herein, we sought to use PE to modulate the pro-
inflammatory effects of a western style diet specifically in the brains of wild type C57BL/6 mice.  
 
Materials and Methods 
Animals and study conditions 
C57BL/6 mice were acquired from Jackson Labs (Bar Harbor, ME USA), acclimated for at 
least two weeks before being weight paired and housed four mice per cage. Mice were housed 
under 12 hour light/dark cycles and were allowed to consume food and water ad libitum. Mice 
were fed either a standard grain- free low fat diet (LFD) (n=8) (Research Diets Cat# D12450B, 
New Brunswick, NJ), or a high fat diet where 45% of calories are derived from fat (HFD) (n=8) 
(Research Diets Cat# D12451, New Brunswick, NJ).  PE was provided by Verdure Sciences 
(Noblesville, IN, USA) and was incorporated directly into LFD (n=8) or HFD (n=8) (1% w/w). Body 
weights and food consumption were monitored weekly. Following 12 weeks of diet 
administration, all mice were anesthetized using isoflurane and sacrificed by cervical dislocation. 
Tissues were immediately harvested and snap frozen in liquid nitrogen. Brains were separated 
into cortex, cerebellum, and hippocampus regions for future analysis. This study and its 
protocols were approved by and conducted in accordance with the University of Rhode Island 





Hepatic Lipid Isolation and Analysis 
Liver lipids from approximately 50 mg of liver tissue were prepared using a chloroform-
methanol extraction method described by More et al44. Triacylglyceride (TAG), Total Cholesterol, 
and Total Lipids were measured using specified kits from Wako Chemicals (Richmond VA 
USA).Total Non-esterified Free Fatty Acids (NEFA) were quantified using a kit from Pointe 
Scientific (Ann Arbor, MI USA).  
Nucleic Acid Isolation from Tissue 
Whole hippocampi were isolated at the time of necropsy and snap frozen for nucleic 
acid isolation. Tissue was subsequently homogenized using Trizol and a dounce homogenizer. 
Homogenized material was then added directly to a Trizol Spin Column (Zymo Research, San 
Diego, CA USA) to isolate nucleic acids according to the manufacturer’s protocol. RNA 
concentration and quality was then determined using a spectrophotometer (Nanodrop, Thermo 
Fisher, Waltham, MA USA)  
 
Gene Expression Analysis  
Genes involved in inflammatory, neurodegenerative, and antioxidant response 
processes were multiplexed from single RNA samples using a custom Quantigene panel (Thermo 
Fisher, Waltham, MA USA). Analysis of the multiplex panel was performed according to the 
manufacturer’s protocols with mean fluorescence intensity quantified using a Bioplex 200 
instrument (Bio-Rad Laboratories, Hercules, CA USA). Genes of interest include IL-1α, IL-1β, IL-2, 
IL-3, IL-4, IL-6, IL-7, IL-9, IL-10, IL-11, IL-13, IL-15, IL-16, IL-18, IL-19, IFNα, IFNγ, TNF, CD38, CD70, 
FASL, MIF, CSF1, CD40LG, LEPR, CD36, MAPT, GSK3β, APP, PPARγ, ITGAM, STING, NOS2, SOD1, 






All gene expression data shown as mean fluorescence intensity (MFI) ± standard error 
(SEM), was analyzed using one way analysis of variance (ANOVA) where p< 0.05 were 
statistically significant. Body weight, tissue weight, and hepatic lipid data are shown as mean ± 
SEM was compared for statistical significance using ANOVA and fisher’s exact test.  Calculations 
were performed using Graphpad Prism (Graphpad Prism Software for Windows Ver 8.0, La Jolla, 






PE supplementation attenuated HFD fed white adipose, liver and body weight gains 
Final body weights of HFD mice (42.6g ± 1.70g) following 12 weeks of a high fat diet exposure 
were significantly increased as compared to LFD mice 30.9g ± 0.92g.  Liver weights were also 
elevated when comparing LFD fed mice (1.26g ± 0.16 g) to HFD fed mice (1.45g ± 0.14g). PE did 
not alter food consumption as compared to control LFD and HFD fed mice. White adipose tissue 
(WAT) was also increased in HFD mice by 112.6% as compared to LFD control mice 
(Supplemental Figure 1). However, the incorporation of PE into HFD feed decreased body, liver, 
and WAT weights by approximately 21.8, 30.4 and 65.6% respectively compared to the HFD 
control group. 
PE reduces hepatic triacylglyceride, total lipid, and non-esterified free fatty acid levels in both 
HFD and LFD Fed Mice 
Given the previous observations, PE’s effect on the liver and fatty acid 
metabolism/catabolism was assessed by measuring total liver lipids, non-esterified free fatty 
acids (NEFA), cholesterol and triacyglycerides (TAG). The HFD increased hepatic total lipid and 
TAG content when compared to LFD controls by approximately 41.1 and 56.1% respectively. PE 
inclusion in the high fat diet significantly reduced total lipid and TAG content by approximately 
41.8 and 60.2% respectively as compared to HFD control mice (Supplemental Figure 2). NEFA 
levels were also elevated in HFD mice by week 12 by 33.4% as compared to Low Fat Diet 
Controls. Moreover, PE inclusion reduced NEFA by 72.5% as compared to HFD control mice and 






PE attenuates the gene expression of key Interleukins and inflammatory mediators in HFD fed 
mice 
HFD fed mice exhibited statistically significant increases in all interleukins (1, 2, 3, 4, 6, 7, 
9, 10, 11, 13, 15, 16, 18, 19) and interferons (α and γ) as compared to the LFD diet fed mice in 
Figures 1 and 2. Gene expression of IL-1α, IL-1β, IL-7, IL-11, and TNF between HFD and HFD+PE 
mice, were significantly decreased by 35.3%, 37.5%, 40.1%, 41.1% and 41.1%.respectively. 
Several other cytokines showed decreasing trends but were not statistically significant. 
Interestingly, IL-2, IL-3, and IL-13 were upregulated by 29.6%, 30.3% and 114.7% respectively 
when comparing HFD to HFD+PE. To limit dietary variables and further elucidate the beneficial 
mechanisms associated with PE consumption, a cohort of mice were administered a LFD+PE 
diet. Interestingly, in the LFD+PE group, IL-1β, IL-2, IL-3, IL-13, and IL-19 were noted with 





PE-supplementation differentially modulates gene expression of antioxidant enzymes, 
reactive species, and neurodegenerative disease associated proteins  
Mice consuming a high fat diet rich in saturated fats and sugars demonstrated the 
observation noted by other rodent studies involving accelerated ageing and poor diet. This HFD 
diet led to the elevation of   genes commonly associated with Alzheimer’s disease: Microtubule 
Associated Protein Tau (MAPT/Tau), Glycogen synthase kinase 3 Beta (GSK3β), and Amyloid 
Precursor Protein (APP) by 1.33, 1.31 and 1.29 fold increase over LFD respectively (Figure 3). 
Each gene saw significant abrogation when comparing HFD+PE with HFD controls by 27.6%, 
24.2%, and 19.4% respectively.  
Nitric Oxide Synthase 2 (NOS2) and Super Oxide Dismutase 1 (SOD1) were significantly 
overexpressed in HFD mice compared to LFD fed mice (76.6% and 39.7% respectively). PE 
supplemented LFD mice increased NOS2 gene expression by 43.4% as compared to the LFD 
control mice (Figure 3). Moreover, SOD1 and NOS2 were decreased by 14.9% and 1.9% as 
compared to the HFD control mice although these decreases were not statistically significant. 
Another major Antioxidant response gene, NFE2L2 (commonly known as NRF2), was significantly 
upregulated by 61.1% in HFD fed mice as compared to LFD controls. The addition to PE to HFD 
reduced this expression of NRF2 by 32.1% as compared to mice fed a HFD. PPARγ, ITGAM and 
STING were augmented in HFD fed mice as compared to their standard chow fed counterparts 
by 53.7%, 62.5%, and 40.6% respectively.  The addition of PE to either diet saw no statistically 






PE addition to HFD modulates fatty acid transport and leptin receptor signaling genes  
The HFD increased  CD38, CD70, FAS ligand, CD40 ligand by approximately 135.3%, 
288.4%, 184.7%, and 88.6% respectively as compared to LFD control mice (Figure 4). 
Macrophage/Microglial associated genes, Macrophage Infiltration Factor (MIF) and Colony 
Stimulating Factor 1 (CSF1) were also significantly upregulated by 46.4% and 74.8% respectively 
in the HFD fed mice. PE supplementation to LFD increased the hippocampal gene expression of 
both MIF and CSF1 by 26.2% and 42.7% respectively.  Interestingly, Leptin Receptor and CD36, 
two major Fatty Acid Transport associated genes, were also markedly increased in HFD fed mice 
by 192.1% and 82.8% respectively. PE supplementation in HFD reduced the gene expression of 
LEPR and CD36 by 41% and 23.7% in the hippocampus respectively. Moreover, HFD+PE mice 







In the case of neurodegenerative diseases, studies have shown that specific dietary 
components may contribute to the weakening of the blood brain barrier and ultimately the 
progressive activation of microglia 20,45. Microglial activation and recruitment, is inherently a 
response to rid the tissue of foreign infection and/or damaged cells. Over time, the signaling 
capacity of microglia to respond to pathogen associated molecules (i.e. lipopolysaccharide or 
bacterial DNA) or damage associated molecules (i.e. nucleic acids from necrotic/apoptotic cells) 
weakens and thus to compensate, more macrophages are recruited further secreting 
inflammatory mediators12,13. This flood of inflammatory stimuli leads to the necrosis and 
apoptosis of neurons and depending on the localization of this degradation, manifests into AD, 
PD or ALS 46.  
Diet as a means of intervention in these initial inflammatory processes, are largely due 
in part to anti-oxidant activity of food sources. PE represents a therapeutically valuable source 
of chemical constituents.  In this study, mice were subjected to a diet rich in saturated fats 
(45%kcal derived from fat) for approximately 12 weeks. Body and Liver weights were 
significantly increased along with glucose and insulin tolerances as a result of this exposure to a 
HFD as compared to their standard chow controls (10% kcal from fat). PE did not alter food 
consumption as compared to control LFD and HFD fed mice. Following 12 weeks of dietary 
intervention, HFD feeding increased body weight, liver weight, and white adipose tissue (WAT) 





We observed that HFD+PE mice also had decreased liver and WAT weights than HFD 
control mice. In addition, PE’s effect on the liver function and lipid regulation was assessed. We 
report that the 45% kcal from fat diet increased hepatic total lipid and triglyceride content when 
compared to a LFD. PE lowered hepatic total lipid and triglyceride content (Supplemental Figure 
2). Additionally, PE supplementation decreased hepatic cholesterol and non-esterified fatty 
acids (Supplemental Figure 2). Taken together, these in vivo findings supported our 
experimental design, that feeding a diet high in fat would generate a mild metabolic syndrome 
phenotype in mice. These findings supported further studies into possible diet effects on 
neuroinflammatory processes.  
 The addition of PE directly to feed reduced in AD-related genes, key inflammatory 
mediators, and even some major receptors associated with fatty acid transport/signaling.  The 
inflammatory mediators, IL-1α and IL-1β were elevated in HFD mice but modulated in PE treated 
HFD mice. IL-1 has been associated as an initial pro-inflammatory response to infection or 
damage but more importantly it may be considered the first step in signaling for tissue repair by 
stimulating helper T-cells (Th17)47,48.  IL-7 which is heavily involved in B-cell proliferation, T-cell 
survival, and stimulation of interleukins in monocytes, was augmented in HFD but abrogated in 
HFD+PE mice49,50.   
Responsible for protecting epithelial and connective tissue, stimulating neuronal 
development and serves as a growth factor for erythroid and myeloid progenitor cells, IL-11, 
was upregulated in HFD mice but significantly attenuated in LFD+PE and HFD+PE mice. The up 
regulation of this gene as a response to oxidative damage could indicate an attempt at 





 Interferon α (IFNα), a pro and anti-inflammatory growth factor, was significantly 
increased in HFD fed mice but the addition of PE to HFD abrogated gene expression to levels 
found in LFD controls (p= 0.06). TNFα, an essential cytokine, growth factor, and intercellular 
signaling molecule, which is seen largely as a pro-inflammatory molecule  was also  significantly 
overexpressed in HFD fed mice but also attenuated to levels similar to LFD control mice. These 
findings suggest that PE modulates the immune responses associated with prolonged exposure 
to a HFD14,46.  
Consistent with findings from other long term diet-induced obesity rodent studies,  Tau , 
GSK3β, and APP, were significantly overexpressed in the hippocampi of mice fed a HFD as 
compared to mice fed a standard LFD20,52,53.  PE’s effect within the hippocampus was seen as 
largely beneficial, as genes responsible for the production of neurotoxic peptides were 
significantly reduced. Moreover, our previous studies evaluating these same endpoints but in 
aged, transgenic  β-amyloid producing mice,  demonstrated decreasing trends  indicating that 
the constituents found in PE at the correct dose and exposure time may prevent the translation 





ITGAM,  which codes for the CD11b or Macrophage associated receptor -1 (MAC-1) was 
elevated in HFD mice and facilitates macrophage and microglial phagocytosis of complement 
coated particles  for degradation54,55. PE fed HFD mice showed a decrease in ITGAM expression 
but not significantly.  FASL a marker for neuronal cell death  was decreased ( although non-
statistically) in PE fed HFD mice by 27.2%56. CD70 appears to have followed a similar trend as 
FASL, where HFD mice show elevated levels of CD70 expression as compared to LFD controls but 
the addition of PE to the HFD produced decreasing  albeit non-statistically significant trends as 
compared to HFD alone.  Macrophage Inhibitory Factor (MIF) and Colony Stimulating Factor 1 
(CSF1) were found to yet again show elevations in HFD mice but with no statistically significant 
reduction in either gene. Similarly, studies with prolonged PE exposure in transgenic APP/PS1 
mouse models, showed attenuation of microgliosis and amyloid plaque deposition57 
HFD increased the gene expression of Fatty Acid Translocase (FAT) (CD36) and the 
Leptin Receptor (LEPR) as compared to their LFD fed mice.  PE addition to HFD decreased CD36 
expression significantly and markedly attenuated LEPR expression as compared to HFD fed mice. 
glucose and insulin intolerance are two major hallmarks associated with leptin receptor 
overexpression in mice 58. Apart from supporting cognitive function, LEPR is implicated in 
neuronal synaptic plasticity and the food reward response 59. While serum leptin levels were not 
measured, literature suggests that low leptin levels in the brain, particularly in the 
hypothalamus, signal for an increase in food intake 60–62.  Leptin hyposensitivity in specific areas 
of the brain may cause hyperphagia leading to obesity. Reducing expression or increasing leptin 




 In the hippocampus, neuroinflammatory and neurodegenerative processes are heavily 
influenced by leptin signaling, and, according to Bonda and colleagues, the result of obesity 
rather than age 63. Evidence from other in vivo studies suggests that leptin resistance in 
Alzheimer’s disease is due to hyperphosphorylation of tau by GSK3β and aggregation of 
neurofibrillary tangles (NFTs)61,62. This increase in circulating leptin in the rest of the brain signals 
for a decrease in food intake and thus promotes weight loss. In hippocampal neurons, aberrant 
leptin signaling causes cognitive deficits over time 62.   
While this current study shows that APP, MAPT/Tau and GSK3β levels were significantly 
increased in HFD fed mice, the addition of PE to the HFD significantly reduced the expression of 
these genes and significantly modulated LEPR signaling as compared to LFD control mice. 
Additional rodent studies using a number of doses of PE are further needed to confirm the 
observation that leptin signaling modulation leads to weight loss and an improvement in neuron 
health in HFD+PE fed mice.  
In the present study, PE supplemented LFD mice expression of a number cytokines and 
receptors such as IL-1 β, IL-2, IL-3, IL-13, IL-19, NOS2, CD38 and CD70 compared to LFD alone.  
The expression of these immune factor genes are varied throughout the brain and play distinct 
roles in specific tissues. For example, IL-1β, which is regarded as an initial inflammatory signal, is 
actually needed to maintain neuronal synaptic plasticity 47. The increase in the expression of the 
interleukins 2 , 3, 13, and 19 which are seen during an influx of lymphocyte infiltration and 
activation as well as microglial activation may be beneficial and prevent neuronal damage64,65.  
Despite gene expression being elevated, actual protein levels may or may not correlate 





The augmentation of these cytokines, as outlined in Table 1, may induce the 
differentiation, proliferation, and recruitment of regulatory T-cells (IL-2), basophils, eosinophils 
(IL-3, 4, 13, 16), CD8+ T-cells (IL-9, 16), B-cells (IL-13), NKT cells (IL-15). IL-18 and IL-19 are 
associated with inducing Th1/Th2 or inducing Th2 cytokine production respectively. Immune cell 
recruitment is needed in response to cell damage to clear necrotic/apoptotic cells or cellular 
debris (fibrils, plaques etc.)64,66. Recruitment of phagocytic macrophages supported by MIF and 
CSF1 expression may be indicative of beneficial macrophages or microglia clearing cellular 
debris. More work in long term diet-induced obesity murine models are needed to confirm this 
observation that PE induces immune response genes as a means to promote clearance of 
damaged cells/debris or pathogenic substances (i.e. endotoxin).  CD38 or Fatty Acid Translocase 
in the hippocampus is required in dendritic cell organization and moreover is involved in cyclic 
ADP ribose and NAD metabolism/catabolism. CD38 knockout models show a protective effect in 
ischemic brain damage but also leads to an increase in poly ADP ribose (PAR) units and increase 
in Poly ADP Ribose Glycohydrolase (PARG)67,68.  An increase in PAR corresponds to an increase in 
PARP1 activity which may deplete intracellular ATP levels leading to cell death68,69. Therefore an 
increase in CD38 may regulate NAD metabolism and prevent premature neuronal cell death.  
CD70 is a Cytotoxic T-cell associated antigen that interacts with Helper B-cells through CD27 in 
order to promote CD8+ CTL survival and function70,71. This increase in gene expression may 
promote a diverse population of lymphocytes to clear damaged or dead cell cells within the 





Total RNA was isolated from these tissues for the simultaneous quantification and 
analysis by way of the Luminex xMAP platform. Luminex technology utilizes magnetic beads 
coated with analyte-specific probes, that, when bound to their target RNA analyte will fluoresce 
at specific intensities when exposed to red and near infrared laser sources. Beads are assigned a 
unique bead number and region which allows for each bead to be distinguished. The data 
acquired from this multiplex is unique in that mean fluorescence intensity or signal is what is 
amplified and not cDNA as with qRT-PCR72–74.  
A notable limitation in this study is the inherent biological variability mouse to mouse75. 
Given the implications of gut microbial transformation of these phytochemicals from PE, 
cohousing effects from four mice per cage, and  individual mouse food consumption may have 
played a role in not only what constituents make it to the brain but at what concentration. 
Previously, our group has determined that the gut microbial metabolites, urolithins, were the 
brain penetrable compounds of PE. However, brains of the mice in this study were not 
perfused76. 
 Given this pilot study utilized a limited number of male mice, future experiments should 
include an appropriate sample size in order to explore the importance of dose and time on these 
immunological endpoints and their relationship with a high fat diet with or without PE 
supplementation. Immunohistochemical staining for microglia and immune cell populations 
(CD4+ vs. CD8+, Regulatory T-Cells, Effector T-cells etc.) within the hippocampus, cortex, and 
cerebellum along with advanced proteomic work of these regions are needed. Proteomics in 
these regions of the brain will address these findings by quantifying the biologically present 







Using a diet-induced obesity rodent model, we sought to examine the potential 
mechanisms associated with PE and obesity associated neuroinflammation. PE was able to 
modulate several key inflammatory molecules including IL-1α, IL-1β, IL-7, IL-11, TNF, MAPT, 
GSK3β, APP and LEPR. PE also augmented several potentially beneficial lymphocyte associated 
cytokines and antigens including IL-1 β, IL-2, IL-3, IL-13, IL-19, NOS2, CD38 and CD70. 
Interestingly several potential pathways could be involved in the beneficial effects derived from 
PE consumption including the modulating the GS3Kβ-TAU-APP pathway, immune cell 
recruitment/differentiation, and leptin signaling. Further in vitro and in vivo studies are 
warranted to fully explore PE at various doses and for specific durations in relevant metabolic 
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Figure 1.) High Fat Diet and High Fat Diet with PE show a general reduction in pro-
inflammatory Interleukins. HFD mice displayed elevated levels of pro-inflammatory cytokines 
and chemotractants. PE supplemented HFD mice showed reduced IL-1, IL-6, and IL-7 while also 
increasing anti-inflammatory cytokines. Statistical significance was calculated using one way 



















Figure 2.) Pro-inflammatory effects of High Fat Diet consumption are modulated with the 
inclusion of PE in feed continued. HFD mice displayed elevated levels of pro-inflammatory 
cytokines and chemotractants. PE supplemented HFD mice showed reduced IL-11, IL-18, IFNα, 
and TNF while also increasing anti-inflammatory cytokines. Statistical significance was calculated 






















Figure 3.) High Fat Diet Fed Mice show increased levels of AD related genes and anti-oxidant 
response genes.  HFD feeding for 12 weeks increased neurodegenerative associated genes 
including cytotoxic T-cell chemotractants, and anti-oxidant enzymes. PE supplementation 
abrogated these markers associated with a HFD intake. Statistical significance was calculated 



















Figure 4.) Macrophage Infiltration, Metabolic Syndrome associated ligand and receptor genes 
are differentially expressed with and without PE inclusion. Statistical significance was 





























DIFF) p value 
IL-1α Induce pro-inflammatory 
cytokines and differentiate 
Th17 cells 
10.81 <0.0001 -6.425 0.0017 
IL-1β 14.72 <0.0001 -6.26 0.0358 
IL-2 Stimulate Tregs, T and B effectors, and NKTs 0.9238 0.0021 0.7429 0.0246 
IL-3 
Activate basophil and 
eosinophils, recruit phagocytic 
cells 
1.708 0.0002 1.013 0.0317 
IL-4 Induce Th2 cells, induce tissue adhesion and inflammation 0.975 <0.0001 0.2917 0.1754 
IL-6 
Infiltration of leukocytes, T-cell 
and B-cell differentiation, 
survival of cholinergic neurons 
2.823 0.0007 -0.7167 0.3802 
IL-7 
Proliferation of B-cells (pre and 
pro), T-cell survival, induce 
Interleukin synthesis in 
monocytes 
13.22 0.0002 -11.73 0.0012 
IL-9 
Growth factor for T and Mast 
Cells, Inhibits Th1 cytokines 
from CD8 T-cells 
1.481 0.0003 -0.4917 0.2225 
IL-10 Immunosuppression via APCs or T-cells1 1.245 0.0056 -0.5417 0.2592 
IL-11 
Growth factor for erythroid, 
myeloid and megakaryocyte 
progenitors. Protect epithelial 
and connective tissue. Inhibits 
monocyte and macrophage 
activity. Neuronal 
development1 
3.807 0.0004 -3.687 0.0021 
IL-13 
Eosinophil and mast cell 
recruitment, activation and 
growth. MHC II up regulation 
on B cells 
2.025 0.0002 3.9 <0.0001 
IL-15 
T-cell proliferation and 
activation (NKT), maintain CD8 
memory, neutrophil and 
eosinophil anti-apoptosis 
6.667 0.026 -1.837 0.5872 
IL-16 
Major chemotractant for 
CD4/CD8 T cells, monocytes, 
mast cells and eosinophils. 
69.56 0.0119 6.75 0.8042 
IL-18 Induces IFNγ with IL-12, activates Th1 or Th2 249 <0.0001 -98.82 0.1221 











DIFF) p value 
IFNα 
Viral Response via adaptive 
immune signaling, stimulate 
DCs antigen presentation, 
macrophage AbDC, Promote 
naïve T-cell growth and tumor 
/virus cell apoptosis 
4.572 0.0022 -2.85 0.0618 
IFNγ 
Th1 cell cytotoxic response and 
differentiation, upregulates 
MHC I and II expression, 
inhibits cell growth (epithelial), 
pro-apoptosis/cell cycle 
modulation. 




initiating or limiting severity 
and duration of inflammatory 
response. 
2.141 0.0004 -1.802 0.0041 
MAPT 
aka Protein Tau, leads to the 
generation of Tau tangles 
(immune reactive peptides)2 
692.7 0.0076 -780.4 0.0074 
GSK3β 
Neuronal development via 
neuronal progenitor 
differentiation.3 
751.8 0.0106 -761.5 0.0161 
APP 
Amyloid Precursor protein, 
normally involved in neuronal 
plasticity and neuronal 
development. Over expression 
leads to plaque formation and 
microglial activation4 
5721 0.0057 4883 0.0369 
PPARγ 
Neuronal depression of 
inflammation associated with 
chronic or acute insult. Glucose 
absorption, lipid balance and 
cell growth/differentiation 
20 0.0073 -2.249 0.7622 
ITGAM 
Leukocyte adhesion, aka 
Macrophage Receptor 1, 
upregulated by TNF, mediate 
complement coated 
macrophage uptake of 
particles for degradation. 
90.02 0.0026 -29.37 0.3086 
STING 
Stimulates Interferon Genes in 
response to viral or internal 
pathogens (microbial DNA). 
Localizes with autophagy 
related proteins 
16.42 0.0032 -3.786 0.518 
NOS2 
Induced by IFNγ, TNF and IL-
1β. Macrophage associated NO 
production, stimulates IL-6 and 











DIFF) p value 
IL-8, stimulate epithelial cell 
growth 
SOD1 
Anti-oxidant response by 
binding to superoxide radial 
molecules 
6170 0.0038 -3242 0.1289 
NFEL2 
aka NRF2, interacts with anti-
oxidant response element, 
stimulating Phase II anti-
oxidant response enzymes 
(HO-1 and NQO-1) 
58.44 0.0001 -49.03 0.0024 
CD38 
TNFa inducible, Dendritic 
organization in hippocampal 
excitatory neurons, humoral 
immune response 
70.13 <0.0001 -8.63 0.5228 
CD70 
TNF ligand, activates T and B 
cells, improves cytotoxic 
function of NK cells, 
proliferation of CD8 T cells 
15.11 <0.0001 -6.3 0.0764 
FASL 
TNF ligand, forms Death 
Domain Complex leading to 
caspase 8 mediated apoptosis 
2.66 0.0002 -1.117 0.1106 
MIF 
Macrophage Migration 
Inhibitor Factor, response to 
bacterial infection (LPS or 
DNA), stimulates cytokine 
release in macrophages 
1824 0.008 -936.9 0.1819 
CSF1 





39.53 0.0008 -12.74 0.2549 
CD40LG 
TNF ligand, stimulate T-cell 
growth and cytokine synthesis 
(IL-4 and IL-10) 
1.339 0.0217 0.4833 0.4241 
LEPR 
Neuronal stimulation and 
plasticity, food reward (anti-
inflammatory).Pro-
inflammatory and increased 
with HFD or metabolic 
syndrome 
13.71 <0.0001 -8.55 0.0039 
CD36 
Aka FAT, transport fatty acids 
into and out of wide range of 
cells. Inhibited by LPS and HDL, 
induced by cholesterol, CSF, IL-
4, insulin and glucose.  






Supplemental Figure 1.) High Fat and Low Fat Diet Effects on Body, White Adipose, and Liver 
Weight with and without PE supplementation. Statistical significance was calculated using one 





Supplemental Figure 2.) Hepatic Triacylglycerides, Total Lipids, and Non-esterified Free Fatty 
Acids are abrogated with PE supplementation in both High Fat and Low Fat Diet fed mice. 
Statistical significance was calculated using one way ANOVA with fisher’s LSD test where p< 0.05 
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Background: Diet-induced obesity is associated with increased circulating levels of endotoxin 
and chronic low grade inflammation. This inflammatory source is linked to the activation and 
recruitment of microglia and is part of the causal link to the pathogenesis of a number of 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis. 
Maple Syrup Extract (MSX), could be a potential source of beneficial phytonutrients capable of 
mitigating these inflammatory processes from occurring. 
Methods: A pilot scale exploratory study with Male C57BL/6 mice fed either a standard grain 
free rodent diet (10% kcal from fat) or a high fat diet (45% kcal from fat) with or without MSX at 
a dose of 0.5% w/w incorporated directly into feed for 12 weeks to yield an aged diet-induced 
obesity phenotype. Mice were sacrificed following 12 weeks and whole hippocampi were 
excised for Luminex xMAP based, QuantiGene multiplex gene expression analysis of 
inflammatory and neurodegenerative disease associated genes. 
Results: Mice fed a HFD for 12 weeks showed elevated expression of Alzheimer’s Disease 
related genes aswell as both pro and anti-inflammatory cytokine/growth factors in hippocampal 
tissues. MSX supplementation in HFD feed allowed for a significant reduction in the gene 
expression of IL-7, IL-11, IL-19, TNFα, IFNα, CD40L, CD70, NFEL2, SOD1, ITGAM, and even LEPR.  
Conclusions: The number of constituents that make up MSX could play multiple roles in organ 
systems. In the hippocampus, MSX may act on not only pro-inflammatory gene expression but 









Obesity and its associated diseases (Type II Diabetes Mellitus (T2DM), Cardiovascular 
Disease, NAFLD, NASH and even cancer) represent a global healthcare and economic burden1. 
Poor diet has been linked to the generation of low grade inflammation systemically2. The gut 
and its numerous microbial inhabitants have been found to be a major source of pro-
inflammatory molecules such as lipopolysaccharide (LPS)3. These pro-inflammatory molecules 
trigger the activation of macrophages which triggers the recruitment and activation of 
additional lymphocytes and leukocytes4,5. The prototypical endotoxin, LPS, which has been 
found in the plasma of obese individuals, has also been found in those diagnosed with 
neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and even 
Amyotrophic Lateral Sclerosis (ALS)6–8. These neurodegenerative diseases are associated with 
their own set of unique and challenging healthcare needs while also adding to the global 
economic burden associated with an ageing population9.  
Neurodegeneration, or the progressive loss in neuron function and viability, is 
associated with ageing and neuroinflammation10. Neuroinflammation is largely governed by the 
resident immune cells of the brain, microglia11. Over time, the brain is insulted with endotoxins 
and environmental toxicants (e.g. Lead, DDT, Mercury etc) 12,13. The Hippocampus, which is the 
center of neurogenesis in the developing brain, is responsible for maintaining basic cognitive 
function and memory, and is one of the first regions to be affected by such insult. The 
hippocampus is also a major site of neurotoxic neurofibrillary plaques and tangles 
accumulation13–15. We can accelerate the ageing process in mice through a diet-induced obesity 
model by feeding mice a diet rich in saturated fats. This effectively models the typical “Western” 




Therapeutic intervention with, insulin sensitizers such as Metformin and 
Thiazolidinediones (e.g. rosiglitazone), lipid and cholesterol reducers (atorvastatin, simvastatin), 
alpha-glucosidase inhibitors,  Non-steroidal Anti Inflammatory Drugs (NSAIDs) and 
cholinesterase Inhibitors induce a number of harmful side effects 17–23.  Complementary and 
natural products in the form of functional foods or herbal medicines have also been considered 
for patients with metabolic syndrome (MetS) on the basis of safety and cost. Despite the 
number of  clinical studies involving  natural products for the management of  MetS have been 
published, our understanding of the actual mechanisms of these products in the brain are still 
being elucidated 24,25. Of the diverse classes of natural products studied, polyphenols  are by far 
the most significantly studied 26,27.   
Polyphenols from a novel, food grade extract derived from a polyphenol rich grade of 
maple syrup termed MSX. MSX has been previously found to have over 60 phytochemicals 
representing a diverse range of polyphenol classes such as Lignans, Coumarins, Phenolic Acids 
and Stilbenes. MSX has been tested in rats at doses up to 1000 mg/kg per day with no 
observable signs of toxicity28. MSX has also been studied for its antibiotic, anti-inflammatory and 
anti-glycative properties29,30.  
Our group has also shown the anti-inflammatory ability of MSX in an in vitro model of 
neurodegeneration with murine microglia and human neurons31. Herein, we sought to use MSX 







Materials and Methods 
Animals and study conditions 
C57BL/6 mice were acquired from Jackson Labs (Bar Harbor, ME USA), acclimated for at 
least two weeks before being weight paired and housed four mice per cage. Mice were housed 
under 12 hour light/darkness cycles and were allowed to consume food and water ad libitum. 
Mice were fed either a standard grain free low fat diet (LFD) (n=8) (Research Diets Cat# 
D12450B, New Brunswick, NJ), or a high fat diet where 45% of calories are derived from fat 
(HFD) (n=8) (Research Diets Cat# D12451 , New Brunswick, NJ.  MSX was produced using food 
grade solvents and purification resins under cGMP conditions through Silicycle, Inc. (Québec, 
Canada) and was incorporated directly into LFD (n=8) or HFD (n=8) (0.5% w/w). Body weights 
and food consumption were monitored weekly. Following 12 weeks of diet administration, all 
mice were anesthetized using isoflurane and sacrificed by cervical dislocation. Tissues were 
immediately harvested and snap frozen in liquid nitrogen. Brains were separated into cortex, 
cerebellum, and hippocampus regions for future analysis. This study and its protocols were 
approved by and conducted in accordance with the University of Rhode Island Institutional 
Animal Care and Use Committee (IACUC) (Approval # AN09-07-004).  
 
Hepatic Lipid Isolation and Analysis 
Liver lipids from approximately 50 mg of liver tissue were prepared using a chloroform-
methanol extraction method described by More et al32. Triacylglyceride (TAG), Total Cholesterol, 
and Total Lipids were measured using specified kits from Wako Chemicals (Richmond VA 
USA).Total Non-esterified Free Fatty Acids (NEFA) were quantified using a kit from Pointe 




Nucleic Acid Isolation from Tissue 
Whole hippocampi were isolated at the time of necropsy and snap frozen for nucleic 
acid isolation. Tissue was subsequently homogenized using Trizol and a dounce homogenizer. 
Homogenized material was then added directly to a Trizol Spin Column (Zymo Research, San 
Diego, CA USA) to isolate nucleic acids according to the manufacturer’s protocol. RNA 
concentration and quality was then determined using a spectrophotometer (Nanodrop, Thermo 
Fisher, Waltham, MA USA)  
 
Gene Expression Analysis  
Genes involved in inflammatory, neurodegenerative, and antioxidant response 
processes were multiplexed from single RNA samples using a custom QuantiGene Luminex 
xMAP  Gene Expression panel (Thermo Fisher, Waltham, MA USA). Analysis of the multiplex 
panel was performed according to the manufacturer’s protocols with mean fluorescence 
intensity quantified using a Biorad Bioplex 200 instrument (Hercules, CA USA). Genes of interest 
include IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-10, IL-11, IL-13, IL-15, IL-16, IL-18, IL-19, 
IFNα, IFNγ, TNF, CD38, CD70, FASL, MIF, CSF1, CD40LG, LEPR, CD36, MAPT, GSK3β, APP, PPARγ, 
ITGAM, STING, NOS2, SOD1, and NFEL2.   
 
Statistical Analysis 
Body weight, Tissue weight and Hepatic lipid  values are shown as mean ± standard 
error (SEM). Gene expression data is shown as mean fluorescence intensity (MFI) ± standard 
error. Data was analyzed using one way analysis of variance (ANOVA) where p< 0.05 were 
statistically significant. Calculations were performed using Graphpad Prism (Graphpad Prism 





MSX attenuated HFD induced white adipose, liver and body weight increases  
Body, liver, and white adipose tissue (WAT) weights at the  time of necropsy were 
significantly increased as a result of HFD. Body weight comparisons between LFD mice (25.8g ± 
0.92g) and HFD fed mice (37.8g ± 1.37g) showed an increase of approximately 46.5% 
(Supplemental Figure 1A). Liver tissue showed a similar increase between LFD and HFD fed mice 
of approximately 50.0% (Supplemental Figure 1B) but a 112.6% increase in WAT weights were 
observed when comparing LFD fed mice to HFD fed mice(Supplemental Figure 1C). Interestingly, 
HFD+MSX mice had significantly lower body, liver, and WAT weights than HFD fed mice by 
18.1%, 57.5%, and 30.7% respectively.  
 
MSX modulates HFD associated increases in serum IL-6 and hepatic lipid accumulation and 
metabolism 
The HFD increased total lipid, non-esterified free fatty acid (NEFA) and triacylglyceride 
(TAG) content by 41.1, 40.6, and 54.3% respectively when compared to LFD control mice. Mice 
fed a HFD in combination with MSX had significantly lower hepatic cholesterol, total lipid, NEFA 
and TAG levels by approximately 40.1, 24.5, 51.0, and 49.3% respectively as compared to HFD 
fed control mice (Supplemental Figure 2).  MSX supplementation with LFD decreased hepatic 
cholesterol, total lipid, NEFA and TAG levels in LFD mice significantly by 45.5, 34.7, 51.6, and 
48.5 % respectively compared to LFD control mice. Serum was also analyzed for pro-
inflammatory marker, IL-6, and was found to be elevated in HFD mice (29.4 pg/ml ± 8.11) as 
compared to LFD (21.8pg/ml ± 3.15 (not statistically significant). The addition of MSX to LFD and 
HFD groups attenuated IL-6 serum concentrations by 53.9 and 59.3% respectively compared to 




MSX significantly reduces the expression of Interleukins and inflammatory mediators in HFD 
hippocampi 
HFD feeding for 12 weeks showed statistically significant increases in all interleukins (1, 
2, 3, 4, 6, 7, 9, 10, 11, 13, 15, 16, 18, 19)  and interferons (α and γ) as compared to LFD fed mice  
Figures 1 and 2.  MSX at a dose of 0.5% w/w was evaluated for its ability to modulate the 
expression of these inflammatory mediators.  HFD+MSX mice demonstrated significant 
modulation of IL-7, TNFα, IL-11, IL-19, and IFNα were significantly decreased by 71.4%, 55.5%, 
34.4%, 18.6% and 79.8% respectively as compared to HFD mice. Several other cytokines showed 
decreasing trends but were not statistically significant. Interestingly, IL-13 and IL-16 were 
upregulated by 74.5% and 97.7% respectively when comparing HFD to HFD+MSX.  LFD+MSX 
mice showed significantly increased expression in IL-1α, IL-1β, IL-2, IL-3, IL4, IL-9, IL-13, IL-16, 
and IL-19. 
 
Gene expression of anti-oxidative enzymes and AD-associated enzymes are differentially 
expressed in both HFD and MSX supplemented HFD mice 
Prolonged exposure of mice to HFD led to the elevation of three key AD-associated  
genes: MAPT (i.e. Tau), GSK3β, and APP by 1.32, 1.31 and 1.29 fold increase over LFD 
respectively (Figure 3). It is worth noting that APP, the processing protein responsible for 
cleaving and releasing Beta Amyloid in the brain, was down regulated with the addition of MSX 
by 13.9% however, the trend was not statistically significant (p= 0.1894).  
Nitric Oxide Synthase 2 (NOS2), a pro and anti-inflammatory protein, was overexpressed 
in HFD mice by 76.6% as compared to LFD mice. Moreover, NOS2 was significantly upregulated 





Antioxidant response genes, Super Oxide Dismutase 1 (SOD1) and Nuclear factor 
(erythroid-derived 2)-like 2(NFEL2) commonly known as NRF2, were significantly upregulated by 
39.7% and 61.1% respectively in HFD fed mice as compared to LFD controls. MSX supplemented 
with HFD reduced the expression of SOD1 (28.0%) and NRF2 (38.0%) as compared to mice fed a 
HFD. PPARγ, ITGAM and STING were also upregulated in HFD fed mice as compared to LFD fed 
counterparts by 53.7%, 62.5%, and 40.6% respectively. HFD+MSX mice showed reductions in the 
expression of the macrophage-associated gene, ITGAM,   by approximately 25.4%.  
 
HFD augments TNF family ligands and Fatty Acid Transport Protein Genes  
CD38, CD70, FAS ligand, CD40 ligand are part of the  TNF family and thus part of the pro-
inflammatory response in diet-induced obesity  33–35. HFD fed mice demonstrated significant 
increases in the expression of these mediators by 135.3%, 288.4%, 184.7%, and 88.6% 
respectively as compared to LFD control mice (Figure 4). MSX added to HFD reduced expression 
of only CD40LG and CD70 significantly as compared to HFD mice by approximately, 59.9% and 
35.2%. HFD mice were found to have significantly upregulated expression levels of 
Macrophage/Microglial associated genes, Macrophage Infiltration Factor (MIF) and Colony 





MSX supplementation to LFD increased the hippocampal gene expression of both MIF and CSF1 
by 21.2% and 117.2% respectively. Leptin Receptor and CD36, two major Fatty Acid Transport 
associated genes, were also markedly increased in High Fat Diet fed mice by 192.1% and 82.8% 
respectively. MSX supplementation in HFD mice reduced expression of LEPR and CD36 by 76.2% 
and 7.4% respectively as compared to HFD control mice. HFD+MSX mice LEPR expression levels 
were found to be similar to LFD control mice  (7.13 MFI ± 0.94) and even the addition of MSX to 
the LFD mice showed further decreased levels of LEPR expression 6.075 MFI ± 0.75 (14.9% 
reduction). CD36, however, showed a non-statistically significant decreasing trend in both LFD 
and HFD groups supplemented with MSX.  
 
Discussion 
Wild type mice were used to model the effects of diet modification on various metabolic 
and immunological endpoints given that diet-induced obesity may lead to chronic inflammation 
and is closely involved in  a variety of disease states including  Non-alcoholic steatohepatitis 
(NASH),  type II diabetes mellitus (T2DM), Neurodegenerative diseases (Alzheimer’s, Parkinson’s 
and Amyotrophic Lateral Sclerosis), and even cancer5,36–38. In the case of neurodegenerative 
diseases, studies have shown that specific dietary components may contribute to the weakening 
of the blood brain barrier and ultimately the progressive activation of microglia39,40. Activation 
and further macrophage recruitment, is inherently a response to rid the tissue of foreign 
infection and/or damaged cells but over time,  the signaling capacity of microglia to respond to 
pathogen associated molecules (i.e. lipopolysaccharide or bacterial DNA) or damage associated 
molecules (i.e. nucleic acids from necrotic/apoptotic cells) weakens and thus to compensate, 





This flood of inflammatory stimuli leads to the necrosis and apoptosis of neurons and depending 
on the localization of this degradation, manifests into AD, PD, or ALS.  
Diet as a means of intervention in these initial inflammatory processes, are largely due 
in part to anti-oxidant activity of food sources26,42. MSX, a food grade phenol-enriched extract 
derived from maple syrup, represents  a chemically unique and under-researched  product with 
over 60 individual chemical constituents including lignans, phenolic acids, coumarins, and 
stilbenes28.  In this study, mice were subjected to a diet rich in saturated fats (45%kcal derived 
from fat) for approximately 12 weeks. Final body weights were significantly increased in HFD fed 
mice as compared to LFD control mice, MSX supplementation to HFD afforded a significant 
reduction in body weight, liver weight, and white adipose tissue. Moreover, MSX incorporation 
in both HFD and LFD showed significantly reduced concentrations of IL-6 in serum 
(Supplemental Figure 3). Hepatic lipids, free fatty acids, and triacylglyceride levels which were 
elevated in HFD mice, were abrogated with MSX supplementation.  Given the presence of 
metabolic syndrome/NASH indicators, further investigation into the effects of diet and 





In this in vivo model of diet-induced obesity, we report, MSX incorporation into feed 
afforded a statistically significant reduction in the gene expression of key inflammatory 
interleukins, interferons and even some major receptors associated with fatty acid transport 
and cell apoptosis. Notably, IL-7 which is heavily involved in B-cell proliferation, T-cell survival, 
and stimulation of interleukins in monocytes, was augmented in HFD but abrogated in HFD+MSX 
mice43,44. IL-11 is responsible for protecting epithelial and connective tissue, stimulating 
neuronal development and serves as a growth factor for erythroid and myeloid progenitor cells, 
was upregulated in HFD mice but significantly attenuated in LFD+MSX and HFD+MSX mice45. 
Similarly, IL-19 which induces Th2 cytokine release in monocytes and macrophages, was 
increased in HFD but decreased in MSX supplemented HFD mice.  Interferon α, was significantly 
increased in HFD fed mice but was significantly abrogated to levels found in LFD controls. TNFα, 
an essential cytokine, growth factor, and intercellular signaling molecule, which is seen largely 
as a pro-inflammatory molecule  was also  significantly overexpressed in HFD fed mice but also 
attenuated to levels at or below LFD control fed mice46.  
AD-related protein, Amyloid Precursor Protein (APP), was significantly elevated in HFD 
fed mice as compared to LFD controls. However, MSX supplementation in LFD or HFD diets 
decreased expression (p value of 0.1894 (HFD vs. HFD+MSX)). Interestingly, Tau and APP were 
significantly upregulated, consistent with findings from other long term diet-induced obesity 
rodent studies 16,47,48. Although, the addition of MSX did not abrogate these markers, it is 
possible that effects of MSX were diminished or masked after such prolonged diet exposure. 
ITGAM or Integrin Alpha Subunit M which is commonly known as Macrophage Receptor 1 (MAC-
1) mediates complement coated particles for macrophage phagocytosis and degradation49,50.  
ITGAM/MAC-1 expression was significantly increased in HFD mice but also modulated in MSX 




Another TNF regulated molecule that was modulated by MSX, was CD40 ligand 
(CD40LG). CD40LG is responsible for the stimulation and growth of T-cell populations while also 
promoting the release of IL-4 and IL-1051. The death receptor ligand, FASL, which was 
upregulated in HFD fed mice was also significantly attenuated in HFD + MSX, fed mice. Taken 
together, the exposure of MSX to mice appears to modulate TNFα and immune response 
pathways mediated by TNF. 
Finally, a fatty acid transport protein CD36 (aka Fatty Acid Translocase, FAT) and Leptin 
Receptor were markedly expressed in HFD mice as compared to their LFD controls.  MSX 
decreased CD36 expression slightly in HFD fed mice (p value = 0.5548) however LEPR was 
significantly decreased in both LFD and HFD fed mice supplemented with MSX as compared to 
LFD fed control mice. As expected, leptin receptor expression is increased in mice with an obese, 
glucose/insulin intolerant phenotype52. Typically, LEPR signaling is not only associated with food 
reward response  but is implicated in neuronal plasticity and is needed to support cognitive 
function53,54. While circulating levels of leptin were not measured in this study, low leptin levels 
in the brain (particularly hypothalamus) signal for increase food intake54,55.  Reducing LEPR 
expression in cell specific or key areas of the brain however, may actually reduce food intake 
and be involved with long term weight loss55,56. In the hippocampus, neuroinflammatory and 
thus neurodegenerative processes are heavily influenced by leptin signaling disruption and the 
result of obesity57. It has been proposed that neuronal leptin resistance in AD is due to 
hyperphosphorylation of microtubule associated protein tau (MAPT, tau) by GSK3β and 





These events prevent neuronal LEPR from binding to leptin signaling which increases 
gene expression of LEPR and thus increases the biosynthesis of leptin. Hippocampal neurons 
which are hyposensitive to leptin  causes cognitive deficits by pre-mature cell death via leptin 
hypersensitive astrocyte/microglia  cytokine secretion or "reactive astrocytosis/microgliosis" 56.  
While this current study shows that MAPT and GSK3β levels were significantly increased in HFD 
only fed mice, the addition of MSX to the HFD did not modulate gene expression. Considerable 
studies are needed to support this observation that weight loss and a decrease in 
neuroinflammation in HFD+MSX mice is attributable to modulation in the leptin signaling 
cascade.  
In the present study, MSX was shown to elevate the expression  of a number cytokines 
such as IL-1 (α and β) IL-2, 3, 4, 9, 13, 15, 16, 18, and 19 as compared to LFD alone and even 
some HFD fed mice. Moreover, some LFD+MSX mice also displayed elevated levels of FASL, 
CD38, CD70, CSF1, and CD36.   The gene expression of these factors are varied throughout the 
brain and during distinct ages. For example, IL-1β, which is regarded as a pro-inflammatory 
signal, is actually needed to maintain neuronal synaptic plasticity58. The increase in the 
expression of the interleukins and cellular factors could be a compensatory mechanism or 
stimulatory response to MSX. Despite gene expression being elevated, MSX may influence 
specific transcription factors which may only be confirmed at the proteomic level. These 
cytokines, as outlined in Table 1, stimulate the proliferation and differentiation of regulatory T-
cells (IL-2), basophils, eosinophils (IL-3, 4, 13, 16), CD8 T-cells (IL-9, 16), B-cells (IL-13), NKT cells 
(IL-15). IL-18 and IL-19 are associated with inducing Th1/Th2 or inducing Th2 cytokine 





The recruitment or infiltration of  immune cells are seen as a necessary response to 
degrade, process, and transport  necrotic/apoptotic cells and cellular debris (fibrils, plaques 
etc.)41,60. Recruitment of phagocytic macrophages as evidenced by CSF1 expression may be 
indicative of beneficial macrophages clearing debris.  That being said, a long term diet-induced 
obesity study is needed to histologically confirm this in vivo observation that MSX induces key 
microglia associated and inflammatory genes to promote the clearance of damaged cells, 
cellular debris, and pathogenic substances.   
The Luminex xMAP platform was used to simultaneously quantify gene expression from 
isolated RNA in these tissues. The platform utilizes analyte-specific magnetic bead coated 
probes, which, when bound and exposed to red and near infrared laser sources, will fluoresce at 
specific intensities. These beads are assigned a unique bead number and region which allows for 
the differentiation of each bead at these various intensities. Normalization to a housekeeper 
gene is not necessary, as greater specificity can be obtained with each probe design unlike qRT-
PCR61–63. A limitation in this study is the inherent biological variability mouse to mouse64. 
Housing conditions of these mice were 4 mice per group and given the implications of gut 
microbial transformation of these phytochemicals from MSX, cohousing effects, individual food 
consumption differences and overall cage to cage variability may have played a role in not only 
what constituents make it to the brain but at what concentration.  
The extent of Blood Brain Barrier penetrability has not been determined with MSX. 
Brains of the mice in this study were not perfused but given that MSX is a complex extract, it is 





One major phytochemical class of MSX, lignans, consists of molecules such as 
Secoisolariciresinol (SECO).  In humans and rodents, SECO is converted to Enterodiol(ED) and 
Enterolactone (EL) by the microbes of the gut65–67. EL in particular has been found to be brain 
penetrable in silico and using passive permeability assays (PAMPA) (data not shown).  
 
Conclusions 
Using a diet-induced obesity rodent model, we sought to examine the potential 
mechanisms associated with MSX and obesity associated neuroinflammation. MSX was able to 
modulate several key inflammatory molecules including IL-7, IL-10, TNF, FASL, and LEPR. 
Interestingly several potential pathways could be involved in the beneficial effects derived from 
MSX consumption including the macrophage recruitment/stimulation, TNF-family death 
receptor mediated apoptosis, and leptin signaling. Further in vitro and in vivo studies are 
warranted to fully explore MSX at various doses in these systems and pathways in addition to 
the identification of representative compounds or metabolites from each major phytochemical 
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Figure 1.) Effects of High Fat Diet and High Fat Diet with MSX show a general reduction in pro-
inflammatory Interleukins. 12 Week HFD feeding afforded a significant increase in pro-
inflammatory cytokines, interferons, and growth factors in response to damage and pathogen 
derived signals. MSX in a HFD abrogated key migratory and immune cell differentiation markers 
such as IL-6 (n.s), IL-7, and IL-10 (n.s) as compared to HFD controls. Statistical significance was 
calculated using one way ANOVA where p< 0.05 *, p< 0.01 **, p<0.001***, p<0.0001****,or not 
























Figure 2.) MSX modulates pro-inflammatory effects of High Fat Diet consumption. 12 Week 
HFD feeding afforded a significant increase in pro-inflammatory cytokines, interferons, and 
growth factors in response to damage and pathogen derived signals. MSX in HFD abrogated IL-
11, IL-19, IFNα, IFNγ (n.s), and TNF gene expression as compared to HFD controls.   Statistical 
significance was calculated using one way ANOVA where p< 0.05 *, p< 0.01 **, p<0.001***, 






Figure 3.) High Fat Diet Fed Mice show increased levels of Alzheimer’s disease                       
related genes and compensatory mechanism associated anti-oxidant response genes. As seen 
is previous diet-induced obesity studies, a HFD caused an increase in the expression of 
neurodegenerative processing proteins (MAPT, GSK3B, and APP) while also stimulating 
macrophage migratory and inflammatory gene signaling (ITGAM, STING) and increasing 
antioxidant response genes (SOD1, and NFEL2). MSX supplementation in HFD feed caused a 
reduction in APP (n.s), ITGAM, SOD1 and NFEL2. Statistical significance was calculated using one 









Figure 4.) MSX modulates gene expression of Macrophage and Metabolic Syndrome 
associated ligands and receptor genes. Mice fed a HFD showed increased macrophage (CD38, 
MIF, and CSF1) and death associated markers (FASL, CD40L) including up-regulation of fatty acid 
transport/metabolism associated genes (CD36, LEPR). The addition of MSX significantly reduced 
CD40LG, CD70 and LEPR.  Statistical significance was calculated using one way ANOVA where p< 



















IL-1α Induce pro-inflammatory 
cytokines and differentiate 
Th17 cells 
10.81 <0.0001 -2.217 0.1677 
IL-1β 14.72 0.0007 -5.01 0.2165 
IL-2 Stimulate Tregs, T and B effectors, and NKTs 0.9238 0.004 0.2143 0.4941 
IL-3 
Activate basophil and 
eosinophils, recruit phagocytic 
cells 
1.708 0.0027 0.7625 0.2032 
IL-4 Induce Th2 cells, induce tissue adhesion and inflammation 0.975 0.0078 -0.025 0.9489 
IL-6 
Infiltration of leukocytes, T-cell 
and B-cell differentiation, 
survival of cholinergic neurons 
2.823 0.0014 -1.217 0.1734 
IL-7 
Proliferation of B-cells (pre and 
pro), T-cell survival, induce 
Interleukin synthesis in 
monocytes 
13.22 0.0044 -20.92 0.0001 
IL-9 
Growth factor for T and Mast 
Cells, Inhibits Th1 cytokines 
from CD8 T-cells 
1.481 0.0368 0.3179 0.6609 
IL-10 Immunosupression via APCs or T-cells 1.245 0.0228 -0.775 0.1972 
IL-11 
Growth factor for erythroid, 
myeloid and megakaryocyte 
progenitors. Protect epithelial 
and connective tissue. Inhibts 
monocyte and macrophage 
activity. Neuronal development 
3.81 0.0018 -3.083 0.0176 
IL-13 
Eosinophil and mast cell 
recruitment, activation and 
growth. MHC II upregulation on 
B cells 
2.02 0.0073 2.533 0.0022 
IL-15 
T-cell proliferation and 
activation (NKT), maintain CD8 
memory antispoptosis 
6.67 0.0215 -0.2405 0.9383 
IL-16 
Major chemotractant for 
CD4/CD8 T cells, monocytes, 
mast cells and eosinophils 
69.56 0.0112 121.9 0.0002 
IL-18 Induces IFNg with IL-12, activates Th1 or Th2 249.00 <0.0001 10.25 0.8489 
IL-19 Induce Th2 cytokines, IL-6, TNFa and IL-10 in monocytes 3.00 <0.0001 -1.35 0.0415 
IFNα 
Viral Response via adaptive 
immune signaling, stimulate 
DCs antigen presentation, 
macrophage  Promote naïve T-















cell growth and tumor /virus 
cell apoptosis 
IFNγ 
Th1 cell cytotoxic response and 
differentiation, upregulates 
MHC I and II expression, inhibts 
cell growth (epithelial), 
proapoptosis/cell cycle 
modulation 




initiating or limiting severity 
and duration of inflammatory 
response 
2.141 0.0033 -2.436 0.0026 
MAPT 
aka Protein Tau, leads to the 
generation of Tau tangles 
(immune reactive peptides) 
692.7 0.0263 175 0.567 
GSK3β 
Neuronal development via 
neuronal progenitor 
differentiation 
751.8 0.0301 387.8 0.2624 
APP 
Amyloid Precursor protein, 
normally involved in neuronal 
plasticity & development. Over 
expression leads to plaque 
formation and microglial 
activation 
5721 0.0488 -3497 0.1894 
PPARγ 
Neuronal depression of 
inflammation associated with 
chronic or acute insult. Glucose 
absorption, lipid balance and 
cell growth/differentiation 
20 0.0097 8.188 0.2769 
ITGAM 
Leukocyte adhesion, aka 
Macrophage Receptor 1 , 
upregulated by TNF, mediate 
complement coated 
macrophage uptake of particles 
for degradation 
90.02 0.0009 -59.6 0.0214 
STING 
Stimulates Interferon Genes in 
response to viral or internal 
pathogens (microbial DNA). 
Localizes with autophagy 
related proteins 
16.42 0.0031 3.964 0.478 
NOS2 
Induced by IFNγ, TNF and IL-1β. 
Macrophage associated NO 
production, stimulates IL-6 and 
IL-8, stimulate epithelial cell 
growth 
















Anti-oxidant response by 
binding to superoxide radial 
molecules 
6170 0.0019 -6077 0.004 
NFEL2 
aka NRF2, interacts with anti-
oxidant response element, 
stimulating Phase II anti-
oxidant response enzymes  
58.44 0.0002 -58.02 0.0003 
CD38 
TNFα inducible, Dendritic 
organization in hippocampal 
excitatory neurons, humoral 
immune response 
70.13 <0.0001 6.503 0.6136 
CD70 
TNF ligand, activates T and B 
cells, improves cytotoxic 
function of NK cells, 
proliferation of CD8 T cells 
15.11 <0.0001 -7.167 0.0372 
FASL 
TNF ligand, forms Death 
Domain Complex leading to 
caspase 8 apoptosis 
2.66 0.0003 -0.9333 0.1914 
MIF 
Macrophage Migration 
Inhibitor Factor, response to 
bacterial infection (LPS or 
DNA), stimulates cytokine 
release in macrophages 
1824 0.0038 38.59 0.9472 
CSF1 





39.53 0.0429 29.44 0.1134 
CD40LG 
TNF ligand, stimulate T-cell 
growth and cytokine synthesis 
(IL-4 and IL-10) 
1.339 0.0071 -1.707 0.0016 
LEPR 
Neuronal stimulation and 
plasticity, food reward (anti-
inflammatory).Pro-
inflammatory and increased 
with HFD or metabolic 
syndrome 
13.71 <0.0001 -15.88 <0.0001 
CD36 
aka FAT, transport fatty acids 
into and out of wide range of 
cells. Inhibited by LPS and HDL, 
induced by cholesterol, CSF, IL-
4, insulin and glucose. 
Controlled by PPARγ in 
adipocytes 








Supplemental Figure 1.) Final Body and Tissue Weights after 12 Weeks of High Fat Diet 
exposure with or without MSX supplementation. Final tissue and body weights were 
significantly elevated through HFD feeding as compared to LFD mice. MSX incorporation into a 
HFD prevented these weight increases. Statistical significance was calculated using one way 








Supplemental Figure 2.) Hepatic Lipid Composition of High Fat Diet fed mice with and without 
MSX. Liver lipid transport and metabolism markers were significantly elevated (less cholesterol) 
as compared to LFD control mice. MSX supplementation caused a significant reduction in TAG , 
NEFA, Total lipids and cholesterol as compared to HFD controls. Statistical significance was 
calculated using one way ANOVA where p< 0.05 *, p< 0.01 **, p<0.001***, p<0.0001****, or 








Supplemental Figure 3.) Serum IL-6 concentrations are abrogated with the addition of MSX in 
Low Fat and High Fat Diets. The pro-inflammatory effects of a HFD were analyzed through ELISA 
and found to be significantly elevated as compared to LFD control mice. HFD mice 
supplemented with MSX saw a significant attenuation in serum IL-6 concentration. Statistical 
significance was calculated using one way ANOVA where p< 0.05 *, p< 0.01 **, p<0.001***, 
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Background: Obesity is a diet-induced disease that stems into numerous pathologies such as 
metabolic syndrome, type II diabetes mellitus, Nonalcoholic Steatohepatitis, Fatty Liver disease 
and even cancer. Chronic low grade inflammation is linked in the etiology of these diseases. 
Polyphenol rich nutraceuticals such as Maple Syrup Extract (MSX) may prevent or reduce the 
severity of these inflammatory processes. 
Methods:  MSX, was evaluated in a murine diet-induced obesity model for a period of 18 weeks. 
Body weight and food consumption were monitored in addition to measuring Fasting Blood 
Glucose, Glucose, and Insulin Tolerance during this study. IL-6 was quantified from serum  
following necropsy. Liver and White Adipose Tissue were excised and weighed at the time of 
necropsy. Livers were sectioned, stained using H&E and scored for histological features 
associated with NASH/NAFLD. Livers were also subjected to bottom-up proteomic analysis for 
significant protein changes.  
Results: 18 weeks of high fat high fructose consumption paired with sedentary behavior caused 
significant increases in body weight, serum IL-6 concentrations, glucose and insulin intolerance 
as compared to low fat diet fed mice.  The addition of MSX 0.5% w/w  exacerbated liver 
steatosis whereas MSX 0.05% w/w  failed to improve histological scoring as compared to high 
fat diet control mice.  
Conclusion: MSX supplementation in high fat diet feed did not ameliorate the progression of 
fatty liver disease in this rodent model as compared to our previous pilot study. The addition of 
MSX at 0.05% did significantly reduce pro-inflammatory serum IL-6 concentrations as compared 
to high fat diet control mice. The addition of fructose and glucose in drinking water combined 
with the duration of diet exposure may have masked the beneficial effects of MSX witnessed in 





Obesity, which affects millions of individuals on a global scale, is linked to a number of 
secondary life-threatening diseases. These diseases such as type II diabetes mellitus (T2DM), 
Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease(NAFLD), Cardiovascular 
Disease (CD), Kidney Disease (KD) and even cancer1–3. These malignances , combined with 
glucose intolerance and insulin resistance make of the spectrum of diseases in  metabolic 
syndrome (MetS) 4,5. These MetS diseases have become more prevalent in the United States and 
contribute to rising healthcare costs. Diet-induced obesity, or the life-long ingestion of saturated 
fats and sugars (fructose and sucrose) may be a causal link to these diseases partially  through 
the dysbiosis of microbes within our gut4,6. By favoring the growth of pathogenic bacteria and 
depleting beneficial populations of bacteria, the luminal concentration of harmful metabolites 
such as lipopolysaccharide (LPS) in the gut increase over time7. 
 These metabolites permeate through  weakened intestinal barriers into the hepatic 
portal system to ultimately effect the Liver and other organ systems (termed endotoxemia)4,7. 
These metabolites, namely LPS, initiate an inflammatory response in circulating monocytes, 
resident macrophages, and immune cells (i.e. B-cells, T-cells)8–10.  The chronic activation and 
subsequent release of pro-inflammatory mediators leads to cell damage and death through 
disrupting mitochondrial function, caspase activation, and in some cases oncogene activation 
inciting cancer growth11,12.  The immune system, therefore, is seen as a potential therapeutic 






While there is no specific treatment for MetS, prophylactic measures namely diet 
change are seen as the most cost effective and impactful15,16.  Incorporation of natural products 
and extracts into a diet have been heavily researched and touted as having fewer side effects 
and lower cost as compared to synthetic products17–21. One under-researched source of these 
immunomodulatory natural products is maple syrup. Derived from the boiling of sap from sugar 
maple species (Acer saccharum L), maple syrup and its derived products (maple sugar, maple 
water etc.) contain over 60 unique phytochemicals22,23. Of these 60 constituents, polyphenols 
are the most abundant along with sugars, vitamins, and minerals23.  
Our group in particular has developed a novel food gradem phenolic-enriched maple 
syrup extract  (MSX) derived from the darker, off-flavor, fractions of maple syrup24. MSX, which 
contains a similar phytochemical profile to maple syrup, contains a number of polyphenols from 
various chemical classes including phenolic acids, lignans, stilbenes and coumarins24.  Previous 
studies from our group demonstrated the anti-inflammatory and anti-glycemic activity of MSX in 
murine and human macrophages, microglia, neurons, and hepatocytes24,25.  MSX has also been 
found to be safe in rats at doses up to 1000mg/kg/day24. 
 In a 12 week pilot study, male C57BL/6 mice were fed a diet rich in fats to promote 
obesity.  MSX supplementation in high fat diet (HFD) fed mice lowered body weight, white 
adipose tissue weight, and liver weight as compared to their HFD controls. Moreover, lipid 
metabolism, fatty acid oxidation, and inflammatory genes were also modulated in livers and 






Previous findings prompted further investigation into the probable mechanisms 
associated with MSX consumption. In the present study, male C57BL/6 mice were fed either a 
standard lab chow or an American lifestyle induced obesity syndrome (ALIOS) diet to promote 
inflammation, glucose intolerance and hepatic fatty acid accumulation. These diets were 
formulated with or without MSX for 18 weeks with the ultimate goal of modulating the 
progression of MetS. 
 
Materials and Methods 
Animal Treatment and Study Design 
C57BL/6 (n=40) aged 4 weeks were purchased from Jackson Laboratories (Bar Harbor , 
ME USA) and housed  with at least two mice per cage under 12 hour light/day cycles. Mice we 
allowed to acclimate for 1 week before having bedding pooled and redistributed weekly for two 
additional weeks. Mice are fed either a Low Fat Diet  (LFD)(12% kcal from fat)(n=8), LFD with 
0.5% w/w MSX (LMSX0.5)(n=6) , LFD with 0.05% w/w MSX (LMSX0.05)(n=6), High Fat Diet 
(HFD)(45% kcal from fat) (n=8), HFD with 0.5% w/w MSX(HMSX0.5)(n=6) or HFD with 0.05% w/w 
MSX (HMSX0.05)(n=6).  Bedding is pooled weekly within treatment groups, mixed and 
redistributed within the treatment group to account for a microbial cohousing effect20,21,26.  
Food intake, body weights and water consumption are monitored weekly. At the end of 18 
weeks,  40 mice were sacrificed and whole blood collected using cardiac puncture. Whole blood 
was centrifuged and immediately separated into two aliquots for future analysis. Mice were 





This study and its protocols were approved by and conducted in accordance with the University 
of Rhode Island IACUC Institutional Animal Use Committee (Approval # AN09-07-004). 
 
Diet Selection 
The ALIOS diet or the High Fat Diet component, models a western diet paired with 
sedentary behavior (placing food directly inside the cage) and sugar rich drinking water. The diet 
consists of hydrogenated vegetable oil (saturated fats) and cholesterol (0.2% w/w) in addition to 
a high sugar water component (42 g/L: 55% w/v Fructose, 45% w/v Glucose)(TD.120330). Diets 
were prepared by Envigo-Teklad (Madison, WI USA) and chosen based on previously cited 
studies that show the development of NASH phenotypes including liver lipid accumulation and 
fibrosis within 16 weeks. The dietary inclusion of cholesterol and high fructose/glucose in 
drinking water also has been shown to further promote the NASH phenotype.9,27,28 A custom 
grain free, phytoestrogen free diet (TD.2020) was used as a Low Fat Diet control.  
 
Glucose Tolerance Test (GTT) and Insulin Tolerance Test (ITT) 
Mice were fasted for 6 hours in both GTT and ITT procedures. Glucose tolerance was 
measured by sampling blood glucose with Bayer Contour Next Glucometers (Ascensia Diabetes , 
Parsippany NJ, USA) after an intraperitoneal (i.p.) bolus of glucose (10ml/kg)(Sigma Aldrich, St. 
Louis, MO USA). Insulin Tolerance was also measured in a similar fashion however measuring 
blood glucose after a single dose (0.75 U/kg) of human insulin (Sigma Aldrich, St. Louis, MO USA) 
was administered via i.p. injection. Blood glucose was recorded  at the following timepoints:  0, 
15, 30 , 45, 60, 90, 120, and 150 minutes following i.p. injection. Average area under the curve 




Histology and Pathology 
Livers were stored in Neutral Buffered Formalin (Sigma Aldrich, St. Louis MO) for at least 
24 hours prior to sectioning and staining. Sections of liver were stained with Hemotoxylin and 
Eosin (H&E) and scored by a board certified veterinary pathologist using the method described 
by Kleiner et al29. Semi-quantitative scores were assigned based on the following 
histopathological features: Lipid Accumulation , Necrosis, Inflammation , Biliary Hyperplasia  
from 0 (0% injury/death) , 1 (<10% injury/death), 2 (10-25 % injury/death), 3 ( 25-40% 
injury/death) , 4 (40-50% injury/death) , or 5 ( >50% injury/death) and Tumor/Lesion incidence 
(0 absent  or 1 present) . Scores were then rank ordered before determining statistical 
significance. Scores from Inflammation , Lipid Accumulation , and Necrosis were combined and 
categorized to establish a NAFLD activity score (NAS) based on van der Heijden et al   where 
samples scored 0-3 represent non-steatohepatitis, 4 borderline steatohepatitis, and scores ≥5 
steatohepatitis30.  
 
Cell Culture of Human Monocytes and Macrophages  
Healthy human donor monocytes (Donor 338) were obtained from Astarte Biologics 
(Bothell, WA USA) and seeded directly into 24 wells plates as stated by vendor protocols. 
Monocytes were then treated with MSX at a dose of 10 μg/mL for 1 hour prior to being exposed 
to Lipopolysaccharide (LPS) (Sigma Aldrich, St. Louis, MO USA) for 23 hours. Resveratrol at 20 
μM was also used for comparison and as a positive control (Sigma Aldrich, St. Louis, MO). DMSO 
at 0.1% v/v was used as a vehicle control (Sigma Aldrich, St. Louis, MO USA). Following 
incubation with LPS for 23 hours, media was centrifuged before being stored for future analysis. 
Secreted TNFα and IL-6 were quantified in media using Biolegend’s Human Deluxe ELISA (San 




THP-1 Human Monocytes were donated by Dr. Nisanne Ghonem of the University of 
Rhode Island’s College of Pharmacy and were maintained using the ATCC’s methods of culturing. 
Cells were maintained in RPMI 1640 Media supplemented with 10% v/v Fetal Bovine Serum 
(Gibco, Grand Island, NY USA), 0.5% Penicillin/Streptomycin Antibiotics and 50 μM of β-
Mercaptoethanol (Biologic Grade, Sigma Aldrich, St. Louis , MO USA).   
Findings with healthy human donor monocytes were further investigated using phorbol 
12-myristate 13-acetate (PMA) (Sigma Aldrich, St. Louis , MO USA) differentiation which were 
carried out according to previously described and optimized methodologies31.  In brief, THP-1 
cells were seeded into 24 well plates at a density of approximately 200,000 cells/mL and allowed 
to incubate for at least 24 hours prior to PMA exposure. PMA was then added directly to each 
well at final concentration of 25nM for 48 hours. Following this period, cells were checked for 
adherence and proper morphology before exchanging existing differentiation media to serum 
free media for at least 24 hours prior to compound treatment.   
As part of a preliminary measure, the effects of MSX on IL-6 and TNFα secretion at 6 and 
24 hours were assayed.  MSX at concentrations of 50 and 100 μg/mL were added to each 
respective set of wells (n=4) for 1 hour before being exposed to LPS at 1 μg/mL for 6 hours. 






THP-1 Macrophage Cytokine Multiplex 
After determining the optimal timeframe for measuring cytokine release in our THP-1 
macrophage system, the experiments were repeated again in 24 well plates but assaying Vehicle 
Control (DMSO), LPS alone (1 μg/mL), Resveratrol at 10 and 20 μM , and  MSX at  0.1, 1, 10 and 
100 μg/mL . Each was pre-treated for 1 hour with the indicated compound or extract before 
being replaced with media containing 1 μg/mL of LPS for 6 hours. After which, media was 
collected, centrifuged, and frozen in aliquots for cytokine analysis. Once again, IL-6 and TNFα 
were measured along with IL-1β, IL-RA, IL-10 , and  MCP-1 using a Luminex xMAP based,  
Procarta Plex Multiplex  (Invitrogen, Carlsbad, CA) .  Observed concentrations were calculated 
using the software available on the Biorad Bioplex 200.  
 
Chemicals and Reagents  
TPCK-treated trypsin, trypsin digested β-galactosidase and mass spectrometer tuning 
solution were purchased from SCIEX, Framingham, MA. Acquity UPLC Peptide BEH C18 analytical 
column and VanGuard pre-columns were procured from Waters Corp. (Waltham, MA). 1,4-
Dithiothreitol (DTT) was obtained from Roche Diagnostics (Indianapolis, IN). Bovine serum 
albumin, sodium deoxycholate and iodoacetamide (IAA) were procured from Sigma Aldrich (St. 
Louis, MO). MS grade acetonitrile and formic acid were purchased from ThermoFisher, 





Mouse liver homogenate preparation  
Approximately 100 mg of mouse liver tissue was cut, weighed and homogenized in 1000 
µl of homogenization buffer (8 M urea, 50 mM Triethylammonium bicarbonate, 5 mM DTT v/v) 
using a bead homogenizer (Omni Bead Ruptor, Kennesaw GA)32. Supernatant was collected after 
spinning at 1,000 g for 5 min. Pierce BCA protein assay kit (ThermoFisher Scientific, Waltham, 
MA) was used to determine total protein concentration. Samples were diluted to a stock 
concentration of 5 mg/ml. 
 
 In-solution trypsin digestion 
  Protein digestion was conducted as described previously with few adaptations 32,33. 
Samples (500 µg protein), along with an internal control of 2 µg bovine serum albumin (BSA), 
were denatured with 25 µL DTT (100 mM) at 35°C for 30 min in a shaking water bath (100 rpm). 
Samples were then alkylated in the dark with 25 µL IAA (200 mM) at room temperature for 30 
min. After alkylation, samples were concentrated using the cold water, methanol and 
chloroform (1:2:1) precipitation method followed by centrifugation at 10000 rpm, 5 min at 10°C. 
Ice-cold methanol was used to wash the protein pellet. The pellet was then suspended in 200 µL 
of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v sodium deoxycholate (DOC). 
Further, 125 µL of the sample was then spiked with TPCK-treated trypsin (12.5 µg) and samples 
were transferred into digestion tubes (PCT MicroTubes, Pressure Biosciences Inc., Easton, MA). 
The barocycler was run at 35°C, for 75 cycles with 60-sec pressure-cycle (50-sec high pressure, 
10-sec ambient pressure, 25 kpsi). Following the first run, 12.5 µg trypsin was added to each 





After the barocycler, 12.5 µL of acetonitrile (1:1, v/v containing 5% formic acid) was added to 
125 µL of digested peptides sample in order to precipitate DOC. Supernatant was collected after 
samples were spun at 10,000 rpm for 5 min at 10°C. Subsequently, 25 µL of the digested peptide 
sample was injected and analyzed using LC-MS/MS.  
 
 LC-MS/MS Analysis 
  Data-dependent analysis (DDA) was performed in positive ionization mode using a 
DuoSpray™ ion source on a Sciex 5600 TripleTOF™ mass spectrometer (AB Sciex, Concord, 
Canada).  Separation was achieved using an Acquity UPLC HClass system (Waters Corp., Milford, 
MA, USA).  Ion spray voltage floating (ISVF) was kept at 5500 V while the source temperature 
(TEM) was 500°C.  Gas 1 (GS1), gas 2 (GS2) and curtain gas (CUR) were set to 55, 60 and 25 psi, 
respectively. Declustering potential (DP), collision energy (CE) and collision energy spread (CES) 
were set at 120, 10 and 5 respectively. During the survey scan, all the ions with a charge state of 
2 to 4, mass range of m/z 300-1250 and exceeding 25 cps were used for MS/MS analysis. Former 
target ions were excluded for 8 sec and the mass tolerance for TOF-MS was 50 mDa with a 100 
milliseconds accumulation time. For the product scan, data were acquired from 100 to 1250 m/z 
with an accumulation time of 75 milliseconds with a total cycle time of 3.5 sec. Product ion 
analysis was done under dynamic accumulation and rolling collision energy dependent on the 
m/z of the ion. All the parameters for SWATH acquisition were similar as described above except 
the following: Source temperature (TEM) was 400°C, GS 1 was 55 psi, and TOF masses were 
collected from m/z 300 to 1500. The total cycle time for SWATH acquisition was 3.95 sec. 
SWATH data was acquired (m/z 400-1100) over 70 SWATH windows per cycles with a window 




Chromatographic separation was achieved over 90 min gradient method at 100 μL/min on an 
Acquity UPLC Peptide BEH C18 (2.1 X 150 mm, 300 Å, 1.7 µm) preceded by an Acquity VanGuard 
pre-column (2.1 X 5 mm, 300 Å, 1.7 µm). Mobile phase A was 100% water, 0.1% formic acid and 
mobile phase B was 100% acetonitrile, 0.1% formic acid).  Gradient conditions used were 98% A 
from 0 to 5 min, 98% to 70% A from 5 to 65 min, 70% to 50% A from 65 to 70 min, 50% to 20% A 
from 70 to 75 min, 20% A was held from 75 to 80 min, and 20% A to 98% A from 80 to 85 min. 
The gradient was held at initial conditions from 85 min until the end of the run to equilibrate the 
column before the start of next run.  The flow was diverted to waste for the first 5 minutes and 
last 10 minutes of the acquisition. Autosampler was maintained at 10°C, and the column was 
kept at 50°C. Trypsin-digested β-galactosidase peptides were injected to monitor TOF detector 
mass calibration every four samples. 
 
Data processing 
 The absolute level of proteins was determined from DDA data using “Total Protein 
Approach” 34. Mouse liver homogenate samples were analyzed as previously described using 
MaxQuant (ver 1.5.2.10)32,34. The proteins were searched on Andromeda search engine against 
the Swiss-Prot human protein database (updated Apr 2018) at 1% false discovery rate (FDR)35. 
Cysteine carbamidomethylation was selected as a fixed modification, and oxidation (M) and 
acetyl (N-term) were used as variable modifications. Label-free quantification was performed 
with a ratio count of 1, and a maximum of two missed cleavages was allowed. All the other 
MaxQuant settings were kept as default values. The absolute protein levels were calculated 





The protein concentrations were expressed as picomoles of protein per gram liver tissue 
(pmol/g liver). 
Normalized Protein conc. (p) = Protein conc (p) × PPGL  [pmol/g liver] 
where PPGL denotes the yield of milligrams of total protein per gram of liver tissue.  
 
Statistical Analysis 
All statistical calculations were performed using Prism version 8.0 (Graphpad, La Jolla CA 
USA). Data is shown as mean ± SEM. Unless otherwise indicated, One-way analysis of Variance 
(ANOVA) with Dunnett’s corrections for multiple comparisons were used to describe statistical 




MSX in LFD and  HFD lowers serum IL-6 concentration in HFD mice and mitgates liver and 
white adipose tissue weight increases  
During the course of this study, approximately half of the mice were allowed to 
consume a low fat diet (LFD) with or without MSX at either 0.5% or 0.05% included in the feed. 
The remaining half were fed a high fat diet composed of 22% hydrogenated vegetable oil , 0.2% 
cholesterol, and  fructose-glucose water (HFD) also with or without MSX at either 0.5% or 0.05% 
w/w included in the diet. At week 18 HFD mice weighed approximately 42.28 g ± 0.81g as 
compared to the LFD group which are approximately 35.55 g ± 0.79 g (Figure 3A). The addition 




At the time of sacrifice, liver, kidneys, adipose tissue (mesenteric, epididymal, and 
brown), small and large intestines, skeletal muscle and brains were  collected, weighed, and 
snap frozen.  HFD mice showed not only increases in liver weight but were noticeably larger and 
visibly steatotic as compared to their LFD fed controls (Figure 4). HFD increased liver weight by 
approximately 140.0% as compared to LFD mice (Figure 3B). Liver weights of HFD+MSX0.5% fed 
mice were approximately 4.378 g ± 0.30g whereas HFD+ MSX0.05% mice weighed just as much 
as HFD control mice (3.156 g ± 0.44 g  vs. 3.052g ± 0.22g  respectively). That trend also held true 
when comparing LFD+MSX 0.5% (1.223g ± 0.03g) and LFD+MSX 0.05% (1.239g ± 0.06g) to LFD 
controls which weighed approximately 1.27g ± 0.02 g.  White adipose tissue (WAT) was also 
weighed and found to be significantly greater in HFD fed mice as compared to LFD mice at 2.190 
g ± 0.10g  and  1.398 g ± 0.19 g respectively  (Figure 3C).  A decrease in WAT weight was only 
observed in the LFD+MSX 0.5% fed mice by approximately 19.5% (1.125 g ± 0.11g ) as compared 
to the LFD control diet fed mice (1.398g ± 0.19 g ).   
 Serum concentrations of pro-inflammatory cytokine, IL-6, were quantified by ELISA. IL-6 
concentrations were found to be significantly increased in HFD fed mice (125.7 pg/ml± 
7.01pg/ml ) as compared to LFD controls (107.4 pg/ml ± 1.46 pg/ml ). Moreover, IL-6 levels were 
significantly abrogated in HFD mice supplemented with MSX at 0.5%(106.8 pg/ml ± 2.40 pg/ml ) 





MSX supplementation improves glucose sensitivity  in HFD mice 
This HFD in particular is designed to model the chronic consumption of high fat, high 
sugar foods common to those found in the American obese population. To confirm the 
phenotype, Glucose sensitivity was measured during Week 12 using a Glucose Tolerance Test 
(GTT). The results indicated that HFD mice have become less sensitive to glucose as compared to 
the LFD fed mice(Figure 1). Despite MSX’s inability to significantly lower Body Weight, sensitivity 
to glucose was significantly affected. The most glucose sensitive group following the 6 hour fast 
is the LMSX0.05% group (AUC of 19529.8 ± 3613 SEM). The addition of MSX to the HFD at high 
doses (i.e.  0.5% w/w) appears to have increased AUC levels albeit slightly (AUC of 64177.3 ± 
3994) as compared to HFD alone (AUC of 55874 ± 4466). Following a two week resting period,  
we performed an insulin tolerance test (ITT) to measure the impact of the ALIOS diet on Insulin 
action following a 6 hour fast (Figure 2). Once again, HFD mice displayed higher tolerances to 
insulin as compared to their LFD alone counterparts with AUC levels of 9964 ± 1522 and 5282 ± 
377.1 respectively. MSX however did not have a significant effect in improving sensitivity to 
insulin across all diet types and doses of MSX.   
 
Tissue Histology confirms ALIOS diet-induced necrosis, lipid accumulation, and inflammation  
H&E staining of liver sections showed the influence of the ALIOS diet on inducing a 
NASH/NAFLD phenotype within an 18 week period. Lipid Accumulation, Necrosis, Inflammation 
and Biliary Hyperplasia were scored from 0-5 based on severity (Table 1 and 2).  Mice 
administered the ALIOS diet showed significant levels of biliary hyperplasia and lipid 
accumulation as compared to LFD treated animals. In the HFD cohort, MSX at 0.5% or 0.05% did 





HFD causes an increase in liver fibrosis and apoptosis proteins and decreases anti-
oxidant/hormone catabolism enzymes and lipid transport, metabolism and catabolism 
proteins 
Liver proteomic analysis of mouse livers from the high fat diet control group 
demonstrated significant modulation in a number of NASH/NAFLD associated proteins. Bottom-
up analysis of approximately 1300 proteins from each liver was filtered to approximately 33 
statistically significant proteins. Fold change as compared to the low fat diet group was then 
calculated and visualized in a functionally grouped heatmap (Figure 6). Volcano plots were also 
utilized to further make comparisons between each treatment group. Of the statistically 
significant proteins identified, CYP2C29 , Hal, CYP1A2, CYP2C50, CSAD, Ftl1 and Abat were 
downregulated in HFD livers as compared to LFD controls(Figure 7). Consequently, Aldh3A2, 
Anxa5, Ehhadh, Scp2, Vim, Plin2, Glul, Fabp2, Apoe1, Decr2, Fgb and GK were upregulated 
compared to LFD mice(Figure 7). The addition of MSX to the high fat diet augmented protein 
levels of Anxa5 and Arhgdia for both 0.5% and 0.05% doses as compared to HFD control livers 
(Figure 8 and 9).  HFD+MSX0.05% showed significantly high levels of Anxa5 and Arhgdia as 
compared to HFD controls (Figure 9). Significant reductions in LFD mice supplemented with MSX 
at 0.5% w/w,  Aldh3a2, Acot2, Scp2, Decr2, Acaa1a, Apoe, Fabp1, , Plin2,  Fabp2, and  Apoa1 
were observed as compared to LFD control mice(Figure 10). Of note, a lack of statistically 




MSX abrogates LPS stimulated pro-inflammatory cytokine release in healthy human donor 
monocytes and PMA differentiated THP-1 Macrophages 
In a preliminary experiment, healthy human donor monocytes were pretreated with 
various concentrations of MSX prior to exposure to LPS for 23 hours. LPS exposure alone 
increased the secretion of pro-inflammatory cytokine IL-6 by nearly 600 fold as compared to 
vehicle, DMSO, control (983.8 pg/ml ± 6.56  vs. 1.64 pg/ml ± 0.52 respectively)(Figure 12A). 
TNFα, which was undetectable in vehicle control, was significantly abundant in media of LPS 
treated monocytes at approximately 212 pg/ml ± 4.35 pg/ml )(Figure 12B). While MSX at doses 
of 10, 50, and 100 μg/ml  significantly decreased IL-6 media concentrations, it was only at  50 
and 100 μg/ml of MSX that were able to significantly reduce the release of TNFα into media by 
11.9 % (186.6 pg/ml ± 3.8 pg/ml ) and 84.8% (32.14 pg/ml ± 1.04 pg/ml ) respectively. 
Resveratrol (RESV) at a dose of 20 μM was used as to compare the effects of MSX to a real world 
highly studied polyphenol. IL-6 and TNFα were both significantly reduced by approximately 
51.9% (473 pg/ml ± 1.79 pg/ml) and 77.6% (47.51 pg/ml ± 0.08 pg/ml) respectively. 
 
To support this finding, THP-1 monocytes were cultured and differentiated into 
macrophages using PMA. As mentioned earlier, differentiated THP-1s were pre-treated with 
vehicle or various doses of MSX for at least 1 hour before the addition of 1 μg/ml of LPS into cell 
culture media for 6 or 24 hours. As seen in the human donor samples, LPS exposure alone 
significantly stimulated the release of IL-6  by 4.6 fold at 6 hours (Figure 13A) and 177.5 fold at 
24 hours (Figure 13C) as compared to the vehicle alone control. TNFα concentrations in LPS only 
treated cells showed similar levels of augmentation at 6 (Figure 13B) and 24hours (Figure 13D) 




 The addition of MSX at 50 μg/ml afforded the most significant reduction of IL-6 at 6 
hours by approximately 49% and by 17% after 24 hours as compared to LPS treated cells alone.  
Cells treated with MSX at a concentration of 50 μg/ml, demonstrated the most significant 
reduction in TNFα by 33.4% after 6 hours as compared to LPS treated controls. After 24 hours, 
neither dose of 50 or 100 μg/ml were able to significantly reduce cytokine secretion into media 
as compared to LPS insulted cells.  RESV at a concentration of 10μM was found to be only 
effective at significantly reducing IL-6 secretion after 6 hours by approximately 16.7%.  
With the consistent observation that a reduction in cytokine release is only apparent at 
a lower dose than a higher dose, we sought to repeat this experiment but expand on the 
number of cytokines measured through multiplexing. Once more, THP-1 monocytes were 
seeded directly onto 24 well plates before being differentiated into macrophages.  Cells were 
treated with vehicle alone, LPS alone or pretreated with MSX (0.1, 1, 10 or 100 μg/ml) or RESV 
(10 or 20μM) for 1 hour prior to LPS exposure for another 5 hours.  As compared to vehicle 
treated cells, concentrations of IL-6, TNFα, IL-1β, MCP-1, IL-1RA, IL-10 were significantly 
increased following LPS exposure by 15.6, 1519, 12.6, 16.9, 14.1 and 40.9 fold respectively 
(Figure 14). RESV (10 and 20 μM) was used again for comparison purposes and showed a 
statistically significant reduction in all secreted cytokines at both concentrations in all but one 
case (RESV at 10 μM and TNFα). TNFα and IL-10 concentrations in vehicle treated cells were not 
detectible. MSX at various doses were the most effective and reduced IL-6, TNFα, IL-1β, MCP-1, 
IL-1RA and IL-10 by 3.00 (1μg/ml MSX), 2.20 (0.1 μg/ml), 2.20 (10 μg/ml), 4.32 (100 μg/ml), 8.20 
(0.1μg/ml), 3.20 (1 μg/ml) fold respectively (Figure 14).  The effects of MSX again at the lower 
doses (namely 0.1 and 1 μg/ml) appeared to continue the trend that was observed in previous 






MSX was evaluated in a murine model of western diet-induced obesity for 18 weeks.  In 
an effort to minimize variability mouse to mouse and from cage to cage, male mice were 
selected over female mice on two major considerations. First, we considered sex differences in 
weight regulation for an extended period of time 36,37. Second, MSX is abundant in 
phytoestrogens which may play vastly different roles in male and female mice with regards to 
adiposity, glucose/insulin response, and the progression or severity of NAFLD 38–41.  To minimize 
cage to cage variability, bedding was collected, pooled within treatment groups, and 
redistributed with fresh bedding every two weeks 21,26. This was done in an effort to address the 
cohousing effect which may be present in mice housed with two or more mice. Mice are 
corophagic and will consume fecal material under times of stress or fasting. Overtime, the 
microbes present in feces will alter the gut microbiome of each mouse potentially causing 
variability in response to each diet and treatment of MSX cage to cage8,26.   
The diet selected for this study was chosen to model the typical consumption of 
saturated fats and sugars common in western diets42,43. Moreover, this is compounded with the 
addition of cholesterol and  high fructose/glucose water to model the intake of sugary 
drinks8,44,45. Sedentary behavior, a necessary component in stimulating obesity in humans, is 
encouraged by placing food directly inside the cage as opposed to in the top mounted feeder.  
This effectively translates to a gradual progression of NASH/NAFLD by 18 weeks, 
glucose/insulin intolerance by 12 and 15 weeks and peripheral inflammation by 18 weeks.  
We know that obesity is a disproportionate intake of high energy foods while expending fewer 
calories. Other diets such as a Methionine-Choline Deficient Diet (MCD), produce liver damage, 
body weight gain, and steatosis, the MCD diet does not produce insulin or glucose resistance nor 




With a 45% kcal diet supplemented with cholesterol, a long term exposure (> 12 weeks) is 
needed to induce weight gain, insulin resistance  but fructose is needed to induce hepatic 
steatosis, steatohepatitis and fibrosis8,27. Similar studies have also reported a mild to moderate 
NASH phenotype in 16 weeks with aged mice 47. While MSX did not lower body weight at week 
18 as in our previous 12 week pilot study, it is possible the effects of age, a more chemically 
diverse diet, and the manner in which MSX was formulated may have contributed to this 
observation. Differences in MSX production and formulation may have altered bioavailability 
and thus could have mitigated any beneficial effects as previously seen in our prior pilot study.  
In this study, MSX was directly encapsulated in casein before cold extrusion into pellet form by 
Teklad.  
Our previous pilot study required fresh incorporation of MSX into ground food prior to 
administration to each cage. Moreover, the constituents of MSX, which are found in heat 
intensive process of developing pure maple syrup, are thermostable and are unlikely to have 
spontaneously degraded at room temperature.  The formulation and preparation of MSX may 
have also effected the dosing each mouse received which may explain why mice in this study did 
not show significant reductions in body weight at week 18.  Despite a lack of body weight loss, 
we observed WAT weights were significantly reduced in mice fed LFD with 0.05% MSX (as 
compared to LFD control diet fed mice). 
Timing and duration of this study was expanded from the initially proposed 12 weeks to 
18 weeks based on findings from two attempts of i.p. glucose and insulin tolerance tests. We 
concluded that mice fed a HFD were glucose intolerant by week 12 and showed intolerance to 
insulin by week 15. Fasting blood glucose was also measured and found to be elevated in HFD 




 HFD+MSX0.5% fed mice showed a decreasing, although non-statistically significant, trend in 
improving insulin sensitivity as compared to HFD control fed mice. LFD mice fed MSX, however 
showed worse sensitivity to insulin despite an improvement in glucose tolerance at week 12 as 
compared to LFD control mice.  MSX at a dose of 0.05% in HFD mice showed a similar decreasing 
trend towards increasing glucose sensitivity as compared to HFD control diet fed mice. Only LFD 
fed mice with MSX 0.05%, showed significantly improved glucose sensitivity.  Taken together, 
Insulin resistance and fasting hyperglycemia, which are hallmarks of MetS, T2DM, and NASH, 
were observed in these mice fed the ALIOS diet. Tissue histology of mice sacrificed at week 18 
confirmed that a NASH and NAFLD phenotype was present based on  scoring for disease specific 
markers such as inflammation, biliary hyperplasia, necrosis, and steatosis. When compared to 
our previous pilot study, MSX supplementation at the same dose (0.5%) appeared to augment 
steatosis and exacerbate the NASH phenotype in ALIOS diet fed mice as evidenced by H&E 
histology scoring. In an 8 week study, Kamei et al showed through transcriptomic analysis of a 
similar 45% kcal study using identically aged male C57BL/6 mice but with their formulation of a 
maple syrup extract at a  dose of 0.06% w/w,  the rate limiting step in triacylglyceride synthesis, 
ACOD1 was found to be significantly upregulated in HFD+MSX mice despite noting a decrease in 
liver TG levels, an increase in serum TG levels, and no appreciable decrease in liver and body 
weight as compared to HFD control mice. Kamei also reported that maple syrup extract 
maintained liver health through immunomodulation or significant downregulation in C-X-C motif 
ligand genes and Serum Amyloid A isoform genes as compared to HFD control mice. These  
findings prompted our group to investigate the physical hepatic protein levels using an 
unbiased, state-of- the- art, mass spectrometry based method to relatively quantify relevant 




Proteomic analysis of  HFD livers compared to LFD control mice revealed  an increase in 
fibrosis/clot forming proteins (Fibrinogen β (Fibb), Vimentin (Vim)),  apoptosis regulators 
(Annexin 5 (Anxa5),  Apoptosis Inducing Factor 1, mitochondrial (AIFM-1))  48–50. Moreover, 
peroxisomal lipid metabolism proteins (Decr2 and Ehhadh), lipid transport proteins (Fatty acid 
bind protein 2 (Fabp 2), sterol carrier proetin 2 (Scp2)), Fatty Acid metabolism proteins (Fatty 
aldehyde dehydrogenase (Aldh3a2), Apolipoprotein a1 (ApoA1)),  and Glycerolkinase (GK), a key 
enzyme in fructose metabolism and triglyceride synthesis were also increased 51–55.  
Interestingly, MSX increased the abundance of Anxa5 and Aifm1 significantly at both 0.5% and 
even more so at 0.05% as compared to HFD controls. LFD mice with MSX showed no aberrant 
levels of Anxa5 or Aifm1.  
A Rho GDP Dissociation Inhibitory protein (Arhgdia), which, when decreased  is 
implicated in metastatic and aggressive hepatocellular carcinoma , was indeed decreased in HFD 
control mice but significantly increased in both HFD+MSX0.5% and HFD+MSX0.05% cohorts 
indicating a possible  anti-carcinogenic mechanism56.  
Enzymes involved in lipid particle removal/catabolsim (Perilipin 2 (Plin2)) and amino acid 
metabolism were also increased in HFD fed mice such as Glutamine synthetase (Glul) 
(Glutamate metabolism and ammonia removal)57,58. Conversely, Taurine biosynthesis associated 
enzyme, Cysteine sulfinic acid  decarboxylase (CSAD) and Histidine Ammonia Lyase (Hal) were 
markedly decreased in HFD mice compared to LFD controls however, HFD+MSX0.5%  livers 





Several cytochrome P450 enzymes (CYP1A2, 2C50, 2C29, 4A12A) which were found to 
be involved in hormone catabolism, fatty acid/xenobiotic detoxification, and steroidogenesis 
were also significantly abrogated in these HFD mice compared to LFD controls59–62. Moreover 
these CYP enzymes were significantly downregulated in MSX supplemented HFD mice at both 
doses. It is still unclear role these specific enzymes play in tandem within the progression of 
NASH/NAFLD however, a decrease in enzymes responsible for the removal of potentially 
oncogenic or DNA damaging endogenous (or exogenous) species may play a significant role in 
hepatic neoplasias including hepatocellular carcinomas warranting future study59.  
Disregulation in Iron homeostasis is associated with NASH to NAFLD onset and 
progression63. Ferritin, specifically ferritin light chain 1 (Ftl1), was significantly decreased in HFD 
control mice with no appreciable effect seen from MSX supplementation.  Finally, a key GABA 
metabolizing protein, Abat, which is critical for proper glucose homeostasis, food intake and 
body weight, was found to be significantly downregulated in HFD control mice and even further 
downregulated in both MSX supplemented cohorts64,65. LFD+MSX0.5% mouse livers also 
confirmed this reduction despite no statistical significance. All in all, proteomic analyses of these 
livers show that MSX may augment certain processes in liver lipid accumulation and hepatocyte 
damage/death. These findings further prompted us to ask, why was MSX harmful in this murine 
study but beneficial in our pilot study? With mouse age and the core diet being identical to our 





 The addition of fructose and glucose in drinking water for this 18 week study could have 
further exacerbated these NASH/NAFLD symptoms and masked any beneficial effects of MSX. 
Fructose is largely metabolized in the liver via a non-insulin dependent manner which leads to 
hepatocellular depletion of ATP and thus an increase in both ADP and uric acid 66,67. The 
generation of this acid leads to oxidative stress, necrosis, and eventually apoptosis of 
hepatocytes. Insulin resistance leads to not only hyperinsulinemia and hyperglycemia but de 
novo lipogenesis 66,67.  The metabolism of fructose combined with an influx of dietary cholesterol  
leads to de novo lipogenesis , enhanced generation of triacylglyceride precursors , and further 
exacerbates hepatic oxidative stress9,51,66,67.  The influence of fructose on lipogenesis in the liver, 
combined with MSX’s inhibition of key lipid and fructose metabolizing enzymes may explain the 
augmented steatotic and necrotic effects in the liver.  
 
The actual gut microbial metabolites of MSX have yet to be identified. 
Secoisolariciresinol (SECO), a significant MSX constituent, is hydrolyzed and metabolized by the 
gut microbiota to Enterodiol (ED) and Enterolactone (EL)68.  In silico and in vitro permeability 
assays  by our group have shown that Enterolactone is most likely to passively permeate 
through the intestinal lining (data not shown). More importantly, EL has also been shown by 
others to have differential  effects in high fat diet fed mice and hepatocyte cultures. In one 
instance, the (-)(levorotatory) stereoisomer of EL ameliorates the effects of a high fat diet in 
mice69. On the other hand, a racemic mixture or even the (+) (dextrorotatory)  EL can cause 
steatosis by down regulating PPARα , CPT1, pAMPK and increasing expression of SREBP1c70.  EL 
was also found to promote extracellular efflux of fatty acids but also inhibited Beta oxidation 
and intracellular lipid metabolism leading to an increase in lipid droplet accumulation, altered 




 Taken together, a thorough understanding of the biologically relevant gut microbial metabolites 
of MSX is needed to fully assess the impact of the other potentially beneficial polyphenol classes 
within MSX.  
Initial in vitro experiments sought to translate findings from murine macrophage 
systems to a more appropriate human model. In this case, Human donor monocytes were 
cultured and exposed to LPS and increased two key pro-inflammatory cytokines: IL-6 and TNFα. 
By pre-treating these cells with MSX at various non-toxic doses and evaluating their 
immunomodulatory role alongside a commonly studied polyphenol, Resveratrol (RESV). 
 Healthy human donor monocytes responded to LPS stimulation for 24 hours by secreting 
significant quantities of IL-6 and TNFα as compared to vehicle control (DMSO < 0.1%). Moreover, 
Resveratrol was also able significantly decrease the release of these cytokines into culture 
medium. MSX also displayed the ability to significantly modulate the release of these cytokines 
at the lowest tested dose of 10 μg/ml.  
Given that a major limitation of using human donor monocytes is variability lot to lot, 
Immortalized THP-1 human monocytes where used to reproduce these findings. THP-1 
immortalized monocytes are often used to study the immunomodulatory properties of a drug or 
natural product/extract 72,73. Moreover they may be co-cultured with other cell types to study 
the regulatory mechanisms associated with cytokine/chemokine secretion in various tissues 72,73.  
In order to sample a broader range and quantity of cytokines in this system, PMA was used to 
differentiate these monocytes to macrophages.  
Following the previously described procedure, the immunomodulatory effects of MSX 
and a comparator compound, RESV, were assayed over the course of 6 and 24 hours. As 
performed previously, differentiated THP-1 cells were exposed to vehicle, MSX or RESV for 1 




 As seen in Figure 13, LPS significantly increased IL-6 and TNFα release as compared to 
vehicle control after 6 hours however; IL-6 and TNFa concentrations were diminished by 24 
hours. RESV at 10μM decreased IL-6 significantly as compared to LPS control wells. More 
importantly, MSX decreased IL-6 and TNFα media concentrations at 6 hours.  This data allowed 
us to confirm the ideal timepoints of quantifying cytokines in the THP-1 system as also observed 
elsewhere 73. Therefore, we repeated this experiment again with the goal of sampling more pro 
and anti-inflammatory cytokines using the Procarta Plex Multiplex. 
Again as with previous experiments, THP-1 monocytes were differentiated using PMA 
and pretreated with either vehicle, RESV (10 or 20 μM) or MSX (0.1, 1, 10, or 100 μg/mL) for 1 
hour prior to LPS (at 1 μg/mL) addition.  LPS significantly increased all measured cytokines as 
compared to vehicle control. Similarly, Resveratrol (particularly at 20 μM) significantly reduced 
the release of these pro-inflammatory cytokines.  Interestingly, MSX at lower concentrations < 
10 μg/mL modulated the release of all cytokines except IL-1β.    
This may be substantiated simply due to the timing of when these media samples were 
removed from culture. IL-1β is an initiator and early signaling molecule of the inflammasome 
with a sorter half-life as compared to IL-6 or TNFα 74,75. Moreover, the cytokine IL-1R receptor 
Antagonist is a direct inhibitor of IL-1β and expressed at the same time under the Toll-Like 
Receptor Myd88 dependent MAPK-ERK pathway76. While no direct mechanism of action studies 
were performed using MSX, we may infer from the Procarta Plex  cytokine data that PMA 
differentiated and LPS stimulated THP-1 macrophages secreted cytokines via the CD14/TLR4 





This pathway includes MAPK and ERK along with AP-1 which may translocate into the 
nucleus to directly bind to pro-inflammatory response elements leading to the production of not 
only pro-inflammatory molecules (IL-1β, IL-6, TNFα, and MCP-1) but also their anti-inflammatory 
counterparts (IL-10, IL-1RA).  Selective inhibition of these targets with representative 






Initially, we hypothesized that MSX prevented metabolic syndrome through its anti-
inflammatory or immunomodulatory effects. In a LPS stimulated immortalized human 
macrophage model, MSX was able to potently abrogate the secretion of pro-inflammatory 
cytokines (IL-6, TNFα, IL-1β, and MCP-1). With much of the LPS signaling pathway known in THP-
2 macrophages, we can only infer that MSX engages the TLR4-MAPK-ERK-NfkB pathway.  With 
such a profound effect on inflammation in vitro, we sought to not only translate these findings 
into another mammalian model but replicate our previous in vivo findings. To do so we used a 
diet-induced obesity murine model that mimicked  lifestyle and consumption risk factors  found 
in the United States  such as  excessive intake of saturated fat, cholesterol  and fructose  
combined with sedentary behavior .This western diet allowed us to truly examine MSX’s ability 
to prevent the onset and/or progression of metabolic syndrome and NASH/NAFLD.  
Our current findings suggest that after 18 weeks of dietary exposure to a high fat -high 
fructose, western style diet, that MSX does not prevent or deescalate the symptoms associated 
with metabolic syndrome and fatty liver disease as supported by necropsy data , liver histology 
and liver proteomics. Despite reducing serum levels of pro-inflammatory IL-6, additional in vivo 
studies with a LFD to HFD switch with and without MSX should be performed to further evaluate 
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Figures and Captions 
 
 
Figure 1.) Week 12 Glucose Tolerance Test (GTT) shows greater insensitivity to Glucose in HFD 
mice as compared to LFD mice.  Mice fed a HFD returned totheir inital fasting blood glucose 
significantly longer as compared to mice fed a LFD. Inclusion of MSX at 0.05% w/w in LFD mice 
also significanly improved sensitivity to glucose as compared nonsupplemented LFD fed mice.  
All data shown as Mean AUC ± SE with all comparisions made to the LFD where p< 0.05 *, p < 












Figure 2.) Week 15 Insulin Tolerance Test (ITT) shows greater insensitivity to Insulin in HFD 
mice as compared to LFD mice.  Mice fed a HFD returned totheir inital fasting blood glucose 
significantly longer following a bolus of insulin (0.75 U/kg) after a 6 hour fast as compared to 
mice fed a LFD. Inclusion of MSX at any concentration did not signifcantly improve sensitivity to 
insulin within any diet.  All data shown as Mean AUC ± SE with all comparisions made to the LFD 


















Figure 3.) Week 18 Necropsy Body Weight, Liver, and White Adipose Tissues Weights. Final 
body and tissue weights following 18 weeks of western diet exposure were significantly 
increased as compared to LFD control mice. MSX0.5% appeared to decrease body and WAT 
weight when added to LFD chow but augmented Liver and WAT in HFD feed as compared to 
their repective diet controls.  Statistical significance was calculated using one way ANOVA where 













Figure 4.) Whole Liver comparisons between Low Fat Diet mice and High Fat diet mice with 
and without MSX supplementation.  Representative images from each treatment group were 
taken to compare gross physiologic changes during the 18 week diet exposure timeline. Low Fat 
Diet (LFD) (A), LFD+MSX0.5% (B), LFD+MSX0.05% (C), HFD (D), HFD+MSX0.5% (E), 





















Figure 5.) Serum concentrations of pro-inflammatory cytokine IL-6 are elevated in HFD mice 
but abrogated by MSX at Week 18. Western diet feeding for 18 weeks afforeded a significant 
increase in pro-inflammatory IL-6 serum concentrations as compared to LFD controls. The 
addition of MSX at both 0.5% w/w and 0.05% w/w to the HFD , caused a significant abrogation 
in IL-6 as compared to HFD control mice.Statistical significance was calculated using one way 








Week 18 Histology Scoring Frequencies  
 
Grade                   
(Severity %)                            










              
(n=6) (%
) 










                 
(n=6) (%
) 
Lipid                                             
Accumulation 
0 (0) 8 (100) 4 (80) 1 (16.6) - - - 
1 (<10 ) - 1 (20) 5 (83.3) - - - 
2 (10-25) - - - - - - 
3 (25-40) - - - - - - 
4 (40-50) - - - 5 (71.4) 1 (16.6) 3   (50) 
5 (>50) - - - 2 (28.5) 5 (83.3)  3  (50) 
Necrosis 
0 (0) 3 (37.5) 4 (80) 5 (83.3) 5 (71.4) 2 (33.3) 3 (50) 
1 (<10 ) 5 (62.5) 1 (20) 1 (16.6) 2 (28.5) 4 (66.6) 3 (50) 
2 (10-25) - - - - - - 
3 (25-40) - - - - - - 
4 (40-50) - - - - - - 
5 (>50) - - - - - - 
Inflammation 
0 (0) 2 (25) 3 (60) 5 (83.3) 2 (28.5) - - 
1 (<10 ) 6 (75) 2 (40) 1 (16.6) 4 (57.2) 4 (66.6) 4 (66.6) 
2 (10-25) - - - 1 (14.3) 2 (33.3) 2 (33.3) 
3 (25-40) - - - - - - 
4 (40-50) - - - - - - 
5 (>50) - - - - - - 
Biliary                  
Hyperplasia 
0 (0) 8 (100) 3 (60) 5 (83.3) - - - 
1 (<10 ) - 2 (40) 1 (16.6) 7 (100) 3 (50) 4 (66.6) 
2 (10-25) - - - - 3 (50) 2 (33.3) 
3 (25-40) - - - - - - 
4 (40-50) - - - - - - 
5 (>50) - - - - - - 
Tumor 
0 (Absent) 7 (87.5) 5 (100) 5 (83.3) 7 (100) 6 (100) 5 (83.3) 
1 (Present) 1 (12.5) - 1 (16.6) - - 1 (16.6) 
              
 





Week 18 Histology P Values 
Feature 
LFD      
vs.    
HFD 
LFD         
vs.      
LMSX0.5% 
LFD           
vs.    
LMSX0.05% 
HFD         
vs 
HMSX0.5% 
HFD          
vs. 
HMSX0.05% 
Lipid                           
Accumulation 
***               
0.002 0.3846 
**                       
0.003 0.1026 0.5921 
Necrosis 0.3147 0.2657 0.1375 0.2861 0.5921 
Inflammation >0.9999 0.2929 0.1026 0.2937 0.2937 
Biliary              
Hyperplasia 
***       
0.0002 0.1282 0.4286 0.0699 0.1923 
Tumor >0.9999 >0.9999 >0.9999 >0.9999 0.4286 
 
Table 2.) Week 18 Histology Scoring P-values. Individual Comparisons between each treatment 
group were made from rank ordered scores derived from the Mann-Whitney Non-parametric t-






Figure 6.) Proteomic Analysis of Week 18 Livers reveal significant increases in NASH/NAFLD 
associated proteins including markers of fibrosis, apoptosis, and lipid regulation.  HFD (HA), 
HFD+MSX0.5% (HB), HFD+MSX0.05% (HC), LFD (LA), LFD+MSX0.5%(LB), LFD+MSX0.05% (LC). 





Figure 7.) Volcano Plot of High Fat Diet and Low Fat Diet Liver Proteins. Statistical significance 
was calculated using multiple t-tests  for comparisons between each treatment groupwhere p< 
0.05 *, p< 0.01 **, p<0.001***, p<0.0001****,or not statistically significant (n.s). 





Figure 8.) Volcano Plot of High Fat Diet and High Fat Diet with MSX 0.5% w/w Liver Proteins  
Statistical significance was calculated using multiple t-tests  for comparisons between each 







Figure 9.) Volcano Plot of High Fat Diet and High Fat Diet with MSX 0.05% w/w Liver proteins. 
Statistical significance was calculated using multiple t-tests  for comparisons between each 








Figure 10) Volcano Plot of Low Fat Diet and Low Fat Diet with MSX 0.5% w/w for Liver 
Proteins. Statistical significance was calculated using multiple t-tests  for comparisons between 







Figure 11.) Volcano Plot of Low Fat Diet and Low Fat Diet with MSX 0.05% Liver Proteins. 
Statistical significance was calculated using multiple t-tests  for comparisons between each 
treatment groupwhere p< 0.05 *, p< 0.01 **, p<0.001***, p<0.0001****,or not statistically 





Figure 12) MSX mitigates initial LPS-induced inflammatory cytokine release in healthy human 
donor monocytes  after 24 hours. Healthy Human Donor Monocytes were pre-treated with 
vehicle (DMSO) , RESV (20 μM), or MSX at 10, 50 or 100 μg/mL for 1 hour before being exposed 
to LPS (1 μg/mL) for 24 hours.  Media was then collected and saved for cytokine analysis using 
respective ELISAs.  Data shown as mean ± SE. All comparisons made to LPS  p < 0.05 * , p < 0.01 























Figure 13.) MSX abrogates LPS-induced inflammatory cytokine release in differentiated THP-1 
monocytes after 6 hrs. Differentiated THP-1 Cells were pre-treated with vehicle (DMSO), RESV 
(10 μM), or MSX ( 50 or 100 μg/mL) for 1 hour before being exposed to LPS (1 μg/mL) for 6 
(Panels A and B) or 24 hours (Panels C and D) .  Media was then collected and saved for cytokine 
analysis with respective ELISAs.  Data shown as mean ± SE. All comparisons made to LPS  p < 









Figure 14.) Low doses of MSX abrogates LPS-induced inflammatory cytokine release in 
differentiated THP-1 monocytes after 6 hrs. Differentiated THP-1 Cells were pre-treated with 
vehicle (DMSO), RESV (20 μM), or MSX ( 0.1, 1, 10 50 or 100 μg/mL) for 1 hour before being 
exposed to LPS (1 μg/mL) for 6 hours.  Media was then collected and saved for cytokine analysis 
with a custom Procarta Cytokine Multiplex and analyzed using the Biorad Bioplex 200.  Data 







Supplemental Figure 1.) Average Body Weights and Food Intake of Each Cage for 18 Weeks of 
Diet Administration.  Effects of each diet with and without 0.5% and 0.05% w/w MSX inclusion 
within either Low Fat or High Fat diet types . Data shown as mean ± SE. All comparisons made to 
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Objectives: Urolithins, ellagitannin-gut microbial derived metabolites, have been reported to 
mediate Pomegranate’s neuroprotective effects against Alzheimer’s disease (AD) but there is 
limited data on their effects against neuroinflammation. Herein, we: 1) evaluated whether 
urolithins (urolithins A and B and their methylated derivatives) attenuate neuroinflammation in 
murine BV-2 microglia and human SH-SY5Y neurons, and 2) evaluated hippocampus of 
transgenic AD (R1.40) mice administered a Pomegranate extract (PE; 100 or 200 mg/kg/day for 3 
weeks) for inflammatory biomarkers. 
Methods: Effects of urolithins (10 μM) on inflammatory biomarkers were evaluated in 
lipopolysaccharide (LPS)-stimulated BV-2 microglia. In a non-contact co-culture cell model, SH-
SY5Y cell viability was assessed after exposure to media collected from LPS-BV-2 cells treated 
with or without urolithins. Effects of urolithins on apoptosis and caspases 3/7 and 9 release 
from H2O2-induced oxidative stress of BV-2 and SH-SY5Y cells were assessed. Hippocampal 
tissues of vehicle and PE-treated transgenic R1.40 mice were evaluated for gene expression of 
inflammatory biomarkers by qRT-PCR. 
Results: Urolithins decreased media levels of NO, IL-6, PGE2, and TNFα from LPS-BV-2 microglia. 
In the co-culture cell model, media from urolithins-LPS-BV-2 treated cells preserved SH-SY5Y cell 
viability greater than media from non-urolithin treated cells. Urolithins mitigated apoptosis and 
caspases 3/7 and 9 release from H2O2-induced oxidative stress of BV-2 and SH-SY5Y cells. While 
not statistically significant, inflammatory biomarkers (TNF-α, COX-2, IL-1, and IL-6) appeared to 
follow a decreasing trend in the hippocampus of high-dose PE-treated animals compared to 
controls.    
Discussion: The attenuation of neuroinflammation by urolithins may contribute, in part, towards 









Neurodegenerative diseases including Alzheimer’s disease (AD), are associated with 
neuroinflammation, which initiates the degeneration of neurons by over-activating microglia in 
the brain.1 Serving as the resident macrophages of the brain, microglia respond to oxidative 
stress derived from tissue damage (i.e. ischemic stroke or trauma) and pathogens to prevent 
further damage to the fragile network of cells.2 Moreover, microglial activation, for instance, 
from bacterial derived lipopolysaccharide (LPS), results in the expression of inflammatory 
mediators and cytokines including nitric oxide (NO), interleukin 6 (IL-6), tumor necrosis factor 
alpha (TNFα), and prostaglandin E2 (PGE2). These inflammatory biomarkers induce a pro-
inflammatory environment by initiating aberrant protein function/formation in the form of 
microtubule associated protein tau (tau) malignancies, β-amyloid, α-synuclein, or Lewy body 
production, finally triggering apoptotic pathways (caspase activation).3 The aforementioned 
process of reactive microgliosis has been extensively studied and is implicated in AD 
pathogenesis.4 Moreover, inflammation of microglia by reactive species from other microglia, 
and exposure to tau, β-amyloid oligomers, or even LPS, activates microglia in a similar 
convergent pathway that ultimately requires the initiation of executioner proteins, caspase 3 
and 7, to continue with programmed cell death.  Therefore, the prevention and/or modulation 
of key pro-inflammatory markers from microglia, achievable through dietary natural products 
and plant foods, are promising dietary strategies for the prevention and possible treatment of 




The Pomegranate (Punica granatum L.) fruit, which is popularly consumed as juice and 
botanical dietary supplements/extracts, is a rich source of ellagitannins, a class of bioactive 
polyphenols, which release ellagic acid on hydrolysis.  Extensive human and animal studies have 
shown that while Pomegranate ellagitannins are not bioavailable, their gut microbial-derived 
metabolites, known as urolithins (formed from colonic microflora biotransformation of ellagic 
acid), achieve detectable concentrations and persist through enterohepatic circulation in vivo.5 
Consequently, urolithins are widely regarded as relevant in vivo compounds which contribute, in 
part, to the biological effects attributed to Pomegranate consumption.5 
Published studies support the neuroprotective effects of Pomegranate juice and 
extracts against AD pathogenesis in several transgenic AD animal models.6-10 Our group has also 
reported on the neuroprotective effects of an ellagitannin-enriched Pomegranate extract (PE) in 
a transgenic AD animal (R1.40) model.11 We further reported that the neuroprotective effects of 
the PE were most likely mediated by urolithins given that its naturally occurring ellagitannins 
and other phytochemicals do not fulfill criteria  (based on in silico computational data) required 
for blood brain barrier penetration.12 Urolithins have been shown to have anti-proliferative and 
anti-inflammatory effects in breast, colon, and neuroblastoma cells13-15 but there is limited data 




Therefore, herein, we: 1) evaluated the in vitro inhibitory effects of urolithins (urolithins 
A and B and their methylated derivatives) against neuroinflammation in murine BV-2 microglia 
and differentiated human neuronal SH-SY5Y cell models and, 2) conducted secondary analysis of 
brain tissues (collected from our previously reported AD animal study with PE)11 for its in vivo 
inhibitory effects on inflammatory biomarkers. 
 
Materials and methods 
Chemicals and General Procedures  
Dimethyl sulfoxide (DMSO) was obtained from Thermo Fisher Scientific (Boston, MA, USA). 
Trans-resveratrol (RESV), all-trans retinoic acid (RA), trypan blue, hydrogen peroxide (H2O2), and 
lipopolysaccharide (LPS) were obtained from Sigma Aldrich (St. Louis, MO, USA). Urolithins (6H-
dibenzo[b,d]pyran-6-one derivatives), namely, urolithin A (3,8-dihydroxy-6H-dibenzo[b,d]pyran-
6-one; UA), methylated-urolithin A (3-hydroxy-8-methoxy-6H-dibenzo[b,d]pyran-6-one; mUA), 
urolithin B (3-hydroxy-6H-dibenzo[b,d]pyran-6-one; UB), and methylated-urolithin B (3-
methoxy-6H-dibenzo[b,d]pyran-6-one; mUB) were synthesized  and validated for purity in our 





Alzheimer’s Disease Transgenic R1.40 Mouse Study 
The AD animal study was conducted as previously reported by our group using an aged 
transgenic R1.40 (B6.129-Tg(APPSw)40Btla/Mmjax) mouse model.11 Briefly, a standardized 
ellagitannin-enriched Pomegranate extract (POMELLA®), obtained from Verdure Sciences 
(Noblesville, IN, USA), was administered to the mice by oral gavage at doses of 100 and 200 
mg/kg for three weeks. All experiments were approved by the University of Rhode Island 
Institutional Action Care and Use Committee and animals were kept under supervision by a 
veterinarian throughout the course of the study and during PE administration. On day 15 of PE 
treatment, the mice began the Morris water maze task, lasting for ten days, followed by a probe 
trial and on day 36, the mice performed the Y-maze task for a single day. The data accumulated 
from the behavioral tests have been previously reported.11  On day 37, mice were euthanized 
and brain tissues were collected and stored at -80°C.  While the majority of the brain tissues 
were utilized for molecular biology assays as previously reported,11 the limited remaining 
hippocampal tissues were used for the current study (further described below). 
RNA Extraction and qRT-PCR of Hippocampal Mouse Tissue for Inflammatory Markers   
For the gene expression studies, RNA was extracted from hippocampal brain tissues using the 
Trizol method as previously described.11 RNA samples were stored at -80 °C until use. The RNA 
concentration was determined by measuring UV absorbance of the sample at 260 nm using a 
NanoDrop 1000 (Thermo Scientific, Wilmington, DE, USA). Total RNA (1 μg) was reverse 




Gene expression was measured in qRT-PCR reactions using SYBR-green with gene-specific 
oligonucleotide primers (Life Technologies, Grand Island, NY, USA) using LightCycler® 480 (Roche 
Applied Science, Indianapolis, IN, USA). Relative mRNA expression of each gene was normalized 
to the β-actin housekeeping gene. The experiment was performed in triplicate. The primers 
utilized were as follows:  
COX2-F: TGGGGTGATGAGCAACTATT; 
 COX2-R: AAGGAGCTCTGGGTCAAACT； 
 IL-1β-F: GACCTTCCAGGATGAGGACA； 
 IL-1β-R： AGCTCATATGGGTCCGACAG；  
IL-6-F： AGTTGCCTTCTTGGGACTGA ； 
 IL-6-R： CAGAATTGCCATTGCACAAC；  
TNFα-F： ACGGCATGGATCTCAAAGAC；  
TNFα-RGTGGGTGAGGAGCACGTAGT. 
Cell Culture  
Human neuroblastoma SH-SY5Y cells were obtained from the American Type Culture Collection 
(Manassas, VA, USA) and were differentiated into neuronal cells as previously reported by our 
group.16 Briefly, the SH-SY5Y cells were treated with retinoic acid (RA) (10 μM) for 7 days while 
changing media every 48 h to ensure proper neurite growth and cell morphology. Murine 
microglia BV-2 cells were kindly provided by Professor Grace Sun from the University of Missouri 




The BV-2 and SH-SY5Y cell lines were maintained using high glucose (4.5 g/L) DMEM/F12 (Life 
Technologies, Grand Island, NY, USA) supplemented with 10% heat inactivated FBS (Life 
Technologies, Grand Island, NY, USA), 1% P/S (100 U/ml penicillin, 100 μg/mL streptomycin 
(Gibco/Life Technologies, Grand Island, NY, USA) and incubated in 5% CO2 at 37°C. The cells 
were harvested by trypsinization (0.25% Trypsin/ EDTA, Life Technologies, Grand Island, NY, 
USA) and were then centrifuged (1500 rpm for 5 min) and resuspended in 10% DMEM/F12.  Cell 
concentrations were determined by counting cells with a hemocytometer and viability was 
assessed by trypan blue staining. All experimental compounds (urolithins at 10 μM; RESV at 20 
μM) were dissolved in DMSO to yield a 10 mM stock solution. Compounds were further diluted 
to yield solutions with a final DMSO concentration of less than 0.1%. Trans-resveratrol (RESV) 
was used as a positive control to demonstrate the protective properties of a well-studied blood-
brain-barrier penetrable dietary polyphenol.  
Cell Viability and Oxidative Stress Assays  
Cellular viability was assessed using the Cell Titer Glo 2.0 (CTG 2.0) one step assay (Promega, 
Madison, WI, USA). Briefly, BV-2 and SH-SY5Y cells were seeded at 100,000 cells/mL to yield 80-
85% confluency in a standard white walled clear bottom 96-well plate. BV-2 cells were exposed 
to experimental compounds (urolithins at 10 μM; RESV at 20 μM) and controls for 1 h prior to 
induction of oxidative stress with 100 μM of H2O2 for 6 h. SH-SY5Y cells were allowed to 




Following the pre-determined incubation period (6, 24, or 48 h), CTG 2.0 was added in a 1:1 
ratio with existing media and mixed for 2 minutes on an orbital shaker prior to luminescence 
measurement (Spectramax M2, Molecular Devices, Sunnyvale, CA, USA).  
Non-Contact Co-Culture Cell Model  
BV-2 and SH-SY5Y cells were co-cultured as previously reported by our group.16 Briefly, SH-SY5Y 
cells were plated in 96 well plates at a density of 100,000 cells/mL and allowed to attach for 24 h 
following seeding. After confirming attachment and a confluency of 85%, SH-SY5Y cells were 
differentiated for 7 days using RA (10 μM) as described above.  Prior to treating the SH-SY5Y 
cells, BV-2 cells were seeded into 12 well plates at a concentration of 100,000 cells/mL and 
allowed to attach for 24 h. Following attachment, BV-2 cells were exposed to experimental 
compounds (urolithins at 10 μM; RESV at  20 μM ) for 1 h prior to exposure to LPS (1 μg/mL) for 
24 h. The medium was collected and centrifuged at 18,000 rcf for 5 minutes at 4°C.  Following 
centrifugation, media from SH-SY5Y cells were removed and replaced with conditioned media 
from the BV-2 cells and left to incubate for 24 h and 48 h after which they were subjected to the 
CTG 2.0 assay to assess cell viability.   
Assessment of Caspase 3/7 and 9 Release   
Caspase 3/7 release within BV-2 microglia and SH-SY5Y neurons were determined by the 
Caspase 3/7 Glo (Promega, Madison, WI, USA) luminescence based assay. Briefly, BV-2 and SH-
SY5Y cells were seeded at 100,000 cells/mL in white walled clear bottom 96 well plates. The BV-
2 cells were allowed to incubate with the experimental compounds (urolithins at 10 μM; RESV at 




SH-SY5Y cells were exposed to experimental compounds for 24 h prior to H2O2 (100 μM) 
exposure for 6 h. Following this incubation period, the Caspase 3/7 or 9 Glo reagent and 
substrate were added in a 1:1 ratio directly to each well. The plate was mixed for approximately 
30 seconds on an orbital shaker prior to incubation at room temperature for 35 minutes. 
Luminescence was recorded using a spectrophotometer (Spectramax M2; Molecular Devices, 
Sunnyvale, CA, USA). 
Measurement of Production of Nitric Oxide Species (NOS)  
BV-2 cells, in 24 well plates (n=4) at 85% confluency (100,000 cells/mL), were serum-starved for 
4 h prior to the treatments. Then the cells were incubated with urolithins (0.5, 1, 5 and 10 μM) 
or RESV (20 μM) for 1 h before lipopolysaccharide (LPS) was added to induce an inflammatory 
response. After 23 h incubation, the cell culture media were collected and centrifuged. The 
supernatants were measured for total nitric oxide (NO) using the Griess assay kit (Promega, 
Madison, WI, USA).  
Measurements of IL-6, PGE2, and TNFα Levels  
Supernatants collected from the NO production experiments (described above) were collected 
and assayed for inflammatory cytokines including IL-6 (Biolegend, San Diego, CA,  USA), PGE2  
(Cayman Chemical, Ann Arbor, MI, USA), and TNFα (Abcam, Cambridge, MA, USA). 
Quantification of IL-6, PGE2, and TNFα were measured using Enzyme Linked Immunosorbent 




Statistical Analysis  
Statistical analysis was performed using Graphpad Prism (Version 6. Graphpad Software, San 
Diego, CA, USA). Data are expressed as means ± standard errors of mean (S.E.M). Each value was 
the result of at least three independent experiments (n = 3). Comparisons between groups were 
analyzed using one-way analysis of variance (ANOVA) with corrections for multiple comparisons 
using Dunnett’s Test. P values were also determined by the Student’s T-test where appropriate. 
Calculated P values less than 0.05 were determined to be significant. 
 
Results  
Urolithins modulate generation of LPS-induced reactive nitrogen species in BV-2 microglia  
The effects of urolithins (UA, UB, mUA, mUB) on neuroinflammation were evaluated in an LPS-
stimulated murine BV-2 microglia cell model (Fig. 1). The urolithins were evaluated at a highest 
concentration of 10 μM, which was non-toxic to the cells as previously reported for human 
neuroblastoma cells,15 and also at lower concentrations of 5, 1, and 0.5 μM. LPS treatment 
increased nitric oxide (NO) concentration in media by more than two-fold (36 vs. 16 μM, 
respectively).  Treatment with 10 μM of UA, UB, mUA and mUB significantly modulated the 
release of NO by 46.2, 23.5, 37.3, and 34.5%, respectively. Similarly, at 5 μM, UA, UB, mUA and 




The well-known neuroprotective polyphenol, resveratrol (RESV), used as a comparative positive 
control, decreased NO levels similar to UA, but at a much higher concentration i.e. 45.5% 
inhibition achievable with 20 μM of RESV which was in agreement as previously reported.17 
Urolithins attenuate release of LPS-induced pro-inflammatory markers in BV-2 microglia  
We next evaluated the effects of urolithins (10 μM) on LPS-stimulated IL-6 and TNFα induction 
in media collected from BV-2 microglia. LPS treatment increased media IL-6 and TNFα 
concentrations by 931.7% and 94.2% respectively, with RESV (20 μM) reducing TNFα and IL-6 by 
32.6% (587 pg/mL) and 21.7% (2007 pg/mL) respectively.  UA markedly decreased media IL-6 
concentration by 31.3%, followed by UB (19.3%), mUB (14.6%), and mUA (8.5%)  (Fig. 2A). 
Among the urolithins, only UA significantly reduced media TNFα concentration by 75.4% (213.8 
pg/mL) (Fig. 2B).  LPS increased media PGE2 concentration by approximately 49.4% (519.2 
pg/mL) whereas RESV (20 μM) reduced media PGE2 concentration by 29.1% (367.9 pg/mL).  
Among the urolithins, only mUB significantly inhibited media PGE2 concentration by 64.7% 




Urolithins mitigate cytotoxicity in a non-contact co-culture model with SH-SY5Y neurons 
Using a non-contact co-culture model as previously reported by our group,16 SH-SY5Y neuronal 
cells were exposed to media collected from BV-2 microglia (treated with vehicle control, RESV, 
urolithins, or LPS alone) and SH-SY5Y cell viability were measured after 24 or 48 h. SH-SY5Y cells 
exposed to LPS-BV-2 media showed reduced viability as compared to vehicle control at both 24 
h (16.1% decrease) and 48 h (48.2% decrease). The positive control, RESV (at 20 μM), 
maintained cell viability with circa 92.5% viable cells up to 48 h. As shown in Fig. 3A, after 24 h, 
all of the urolithins (at 10 μM) significantly sustained SH-SY5Y cell viability (>100 %) greater than 
the LPS treatment (cell viability circa 80%). After 48 h (Fig. 3B), only UA and mUA significantly 
maintained cell viability (92.7% and 86.5% viable cells, respectively) relative to that of the LPS 
treatment (67.7% viable cells).  
Urolithins reduce H2O2 oxidative stress induced apoptosis and caspases 9 and 3/7 release in 
BV-2 microglia and SH-SY5Y neurons 
Next, we evaluated the protective effects of urolithins on H2O2 induced oxidative stress of BV-2 
microglia and SH-SY5Y neurons. Briefly, BV-2 and SH-SY5Y cells were pre-treated with urolithins 
(1 h and 24 h respectively) after which the cells were exposed to H2O2 (for 6 h). Following this 6 
h incubation with H2O2, cell viability of BV-2 decreased to 68.2%. When pre-treated with RESV 




As shown in Fig. 4A, the urolithins (at 10 μM) maintained BV-2 cell viability after exposure to 
H2O2 as follows: UA (83.6% viable cells), UB (79.3% viable cells), mUA (76.5% viable cells), and 
mUB (83.1% viable cells). Similarly, as shown in Fig. 4B, urolithins protected SH-SY5Y cells after 
exposure to H2O2 (51.4% viable cells) with UA maintaining cell viability above 90% while mUA, 
mUB, and UB maintained/ increased viability by 12.4, 5.8, and 1.4%, respectively.  
We then evaluated the effects of urolithins on caspases 9 and 3/7 release of the BV-2 microglia 
and SH-SY5Y neuronal cells exposed to H2O2 induced oxidative stress (as described above).  H2O2 
caused approximately 129.1% and 509.6% increase in caspase 9 activity as compared to un-
treated vehicle control in BV-2 and differentiated SH-SY5Y, respectively (Fig. 5).  Similarly, H2O2 
caused approximately 423.2% and 121.7% increase in caspase 3/7 activity as compared to un-
treated vehicle control in BV-2 and differentiated SH-SY5Y, respectively (Fig. 6). The positive 
control, RESV (at 20 μM), also significantly attenuated caspase 9 release in the BV-2 (44.4% 
decrease) and SH-SY5Y (62.6% decrease) cells (Fig. 5), Similarly, RESV (at 20 μM) also 
significantly attenuated caspase 3/7 release in the BV-2 (46.5% decrease) and SH-SY5Y (54.4% 
decrease) cells (Fig. 6).  In BV-2 microglia the highest decrease in caspase 9 activity was 
observed for mUB (62.9%) followed by UA (61.3%), UB (57.8%), mUA (60.8%), respectively (Fig. 
5A). In SH-SY5Y, the highest decrease in caspase 9 activity was observed for UB (78.8%) followed 




Among the urolithins, only UB (12.0% decrease) and mUA (17.8% decrease) significantly 
attenuated caspase 3/7 release in BV-2 microglia (Fig. 6A). All of the urolithins, except UA, 
significantly decreased caspase 3/7 release in SH-SY5Y as follows: UB (35.9%), mUA (59.2%) and 
mUB (72.0%) (Fig. 6B).  
 
Pomegranate extract (PE) appears to follow a decreasing trend in reduction of gene 
expression of inflammatory biomarkers in excised hippocampus tissues of AD transgenic R1.40 
mice  
We conducted secondary analyses of excised whole sections of the hippocampus collected from 
our previously reported11 AD transgenic R1.40 mouse study. While not statistically significant, PE 
treatment (at 200 μg/mL) appears to follow a decreasing trend in the transcription levels of 
COX-2, IL-I, TNFα, and IL-6 as compared to the control animals (Fig. 7)  
 
Discussion 
Exposure to environmental toxins and infectious agents, along with diet, have a 
profound impact on neuroinflammation, and consequently, brain health.18 Polyphenol-rich plant 
foods have been reported to inhibit neuroinflammation in both in vitro and in vivo studies19, 20 
and several, including curcumin,21 olive oil,22 grape,23 and Pomegranate,6-11 show protective 
effects against neurodegenerative diseases including AD in cell and rodent models.  However, 
the poor systemic bioavailability coupled with low blood brain barrier penetrability of 
polyphenols remain as major challenges towards their advancement as dietary agents for AD 




 Interestingly, the biotransformation of polyphenols by human gut microflora into 
bioavailable and bioactive gut microbial-derived metabolites has attracted considerable 
research interest in the context of human health including neurodegenerative diseases.25-27  
Moreover, polyphenol-derived gut microbial metabolites have been reported to achieve 
detectable and physiologically relevant levels in circulation and some even cross the blood brain 
barrier.28 
As previously noted, the Pomegranate shows neuroprotective effects in several AD 
animal models,6-11 but while its naturally occurring ellagitannins, are not bioavailable, their gut 
microbial derived metabolites, namely, urolithins, are detectable in circulation25 and can 
potentially cross the blood brain barrier.12,28 Our group has previously reported on the 
neuroprotective effects of a PE which we proposed were largely mediated by urolithins rather 
than the naturally occurring Pomegranate ellagitannins.11, 12 While recently urolithins have been 
evaluated for their anti-inflammatory effects in human neuroblastoma SH-SY5Y cells,15 there 
have been no similar studies in human neuronal SH-SY5Y cells (achieved by differentiating the 
neuroblastoma SH-SY5Y cells) nor in microglia cells with these compounds. Also, while 
punicalagin, a major Pomegranate ellagitannin has been reported to show anti-apoptotic effects 
of rat PC12 cells by mitigating oxidative stress,42 studies on the relevant circulating compounds, 
namely, the urolithins, are necessary.   Therefore, based on our hypothesis that urolithins 
mediate the neuroprotective effects of PE, secondary analyses of the hippocampal tissues 
collected from our previous AD animal study,11 appeared to show a decreasing trend in gene 




Variability from mouse to mouse was a confounding factor in that study warranting 
further studies using a larger sample size of animals.  Also, unfortunately, because of limited 
brain tissues remaining from that study we were unable to isolate protein to conduct western 
blot analyses for protein expression.  Moreover, we lack direct evidence confirming the 
presence of urolithins in brain tissues (for e.g., achievable by analytical methods such as mass 
spectrometry) collected from the transgenic AD animals. Thus, our group’s future planned 
studies include conducting additional animal studies using relevant doses of purified urolithins 
to elucidate their pharmacokinetics, pharmacodynamics, and mechanism/s of action. Notably, 
UA was recently reported to induce auto/mitophagy in vitro and in vivo which may be an 
important consideration in the neuroprotective effects of these compounds.29  
Next, we designed a series of in vitro studies using BV-2 microglia and SH-SY5Y neuronal 
cells to explore the effects of the urolithins against neuroinflammation. The mechanisms of cell 
death, specifically within neurons, are well documented and attributable to oxidative stress by 
radical species via the intrinsic apoptosis pathway.30, 31 Moreover, the exposure of neurons to 
damage and pathogen associated proteins/markers directly from neighboring cells (for e.g. 
microglia and astrocytes) are involved in the initiation of the extrinsic pathway of apoptosis.32 
Intervention in these pathways or the modulation of the production of pro-inflammatory 
markers are potential methods for treating complex neurodegenerative diseases. On this basis, 
we have shown that urolithins may prevent neuronal cell death by preventing the generation of 
reactive nitrogen species and major pro-inflammatory cytokines including IL-6, PGE2, and TNFα. 
These inflammatory biomarkers have been implicated in vitro and in vivo in the production of β-





To evaluate the effects of urolithins on oxidative stress, we used hydrogen peroxide 
(H2O2), a well-known inducer of the intrinsic oxidative stress induced apoptosis pathway, to 
evaluate the protective effects of the compounds on microglia and neurons.34-36 Moreover, we 
probed the penultimate and ultimate checkpoint proteases responsible for cell death, namely, 
caspases 9, 3/7 respectively. Cysteinyl-aspartate proteases (caspases) are the executioner 
proteins of a dying cell which act on DNA repair enzymes ultimately leading to DNA 
fragmentation and cell death. This activation not only represents the final step in apoptosis but 
occurs in the microglia of individuals with AD-like conditions when exposed to either oxidative 
stress via free radicals or pro-inflammatory molecules from activated microglia or dying cells.37 
Caspases 3 and 7 are the major caspase isoforms involved in apoptosis and thus represent 
possible therapeutic targets to prolong cell life.37   
Thus, by pre-treating BV-2 murine microglia with urolithins and then inducing oxidative 
stress in these cells with H2O2, the extent of caspases 3 and 7 release were measured. Our 
findings show that urolithins mitigated acute oxidative stress within microglia and neurons by 
maintaining cell viability and mitigating caspases 3 and 7 activity. Upstream of the caspase 
mediated intrinsic apoptosis pathway, effector caspase 9 activity was also diminished by 
urolithins. Taken together, urolithins may exert neuroprotective effects by preventing oxidative 
stress mediated apoptosis by preventing caspase activation.   Moreover, we also showed the 
effects of urolithins on microglial modulation using a non-contact co-culture cell model with 




Indeed, media from the urolithins treated BV-2-LPS cells increased cell viability of SH-
SY5Y cells greater than media collected from non-urolithin treated BV-2-LPS cells.  A limitation 
of this assay includes the origin of cells that were used, namely, microglia and neuronal cells of 
murine and human origin, respectively. While it would have been more ideal to use human 
instead of murine microglia, it should be noted that human microglial cells are restricted to 
limited number of passages before they begin to undergo drastic morphological changes. Also, 
the secretome of murine microglia differs from human microglia and responsiveness of BV-2 
murine microglia to certain immunostimulatory molecules may also be inconsistent with their 
human counterpart.38 Another limitation of our study could arise from the differentiation 
process of converting human SH-SY5Y neuroblastoma cells into neuronal cells (using retinoic 
acid for a period of 7 days). It is possible that incomplete differentiation of the cells could lead to 
variability in sensitivity to neurotrophins/neurotoxins,39 viability, and ultimately, protein 
expression.36 
In the in vitro experiments, we chose the well-known polyphenol, namely, resveratrol 
(RESV) as a comparative positive control. However, there is considerable variation reported in 
RESV concentrations which are required to achieve ‘neuroprotective’ effects in SH-SY5Y, BV-2, 
and other similar cells.40, 41  Herein, we evaluated RESV at 20 μM since higher concentrations 
were toxic to the BV-2 and SH-SY5Y cells while lower concentrations were not neuroprotective.  
In contrast, the urolithins were all evaluated at a non-toxic dose of 10 μM which was in 




Thus, while further animal studies are required to ascertain whether circulating 
urolithins can achieve these concentrations in the brain, the current study provides useful 
mechanistic data supporting the anti-neuroinflammatory effects of urolithins, which may 
contribute to the overall neuroprotective effects reported for Pomegranate.  
 
Conclusions 
Although the pathogenesis of AD is still under discussion, the link between 
neuroinflammation and neurodegenerative diseases has been well established. Numerous 
studies have shown that long term exposure to toxicants, frequent infections, and poor diet can 
negatively impact the blood brain barrier, increasing the risk of microglial activation and thus 
increasing the secretion of pro-inflammatory molecules that would ultimately lead to the pre-
mature termination of neuronal and astrocytic cells. Intervention during this microglial 
activation process has become an attractive target in the disruption of the pathogenesis of AD. 
Other targets for this disease include Aβ export/ablation drugs in addition to 
acetylcholinesterase inhibitors. Currently, the available drugs that are administered to patients 
are only palliative and thus do not address the underlying cause of this disease. However, 
natural products, including certain berries and fruit such as Pomegranate, show promise as 
dietary intervention strategies for AD prevention and/or treatment. In summary, herein, we 
report that PE-treated animals appeared to show decreasing trend in gene expression of 
inflammatory cytokines in brain tissues in vivo and that urolithins prevent the over-activation of 
microglia and maintain viability of neurons in vitro. Further investigation into brain penetrability 
and the molecular target/s of urolithins are warranted in order to elucidate their specific 
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Figure 1 Urolithins attenuate LPS-stimulated elevation of media nitric oxide (NO) in murine 
microglial cells. Pre-treatment of microglia with vehicle, resveratrol (RESV), or urolithins for 1 h 
was followed by a 24 h incubation period with LPS. Release of NO (as measured by the Griess 
assay) was attenuated by urolithins at concentrations from 1-10 μM. Data expressed as mean ± 
standard error (n=4).Comparisons are made to LPS where  P<0.05 * , P< 0.01 ** , P< 0.001 *** , 













Figure 2 Urolithins modulate the release of pro-inflammatory cytokines in LPS stimulated 
murine BV-2 microglia. BV-2 microglia were pre-treated with vehicle, urolithins, or resveratrol 
(RESV) prior to LPS exposure for 24 hours. When incubated for 1 h prior to LPS stimulation, 
urolithins modulated the secretion of IL-6 (A) in cell culture media. UA significantly inhibited the 
release of TNFa (B) whereas only mUB significantly inhibited PGE2 levels (C). Data expressed as 
mean ± standard error (n=4). Comparisons are made to LPS where P<0.05 * , P< 0.01 ** , P< 










Figure 3 Urolithins maintain human neuronal SH-SY5Y cell viability when exposed to LPS 
conditioned media from microglia. BV-2 microglia were pre-treated with vehicle, urolithins, or 
resveratrol (RESV) prior to LPS exposure for 24 hours. LPS conditioned media was then 
centrifuged and introduced to differentiated SH-SY5Y cells. Viability of differentiated SH-SY5Y 
cells was significantly sustained after 24 and 48 hours of urolithins as compared to the viability 
of cells containing conditioned BV-2 –LPS media. Data expressed as mean ± standard error (n=3). 






Figure 4  Urolithins maintain BV-2 murine microglia and SH-SY5Y human neuron cell viability. 
BV-2 microglia were pre-treated with vehicle, urolithins, or resveratrol (RESV) prior to LPS 
exposure for 24 hours. When exposed to the intrinsic oxidative stressor hydrogen peroxide 
(H2O2) for 6 hours following either a 1 hour  or 24 hour pre-treatment of urolithins,  cell viability 
is significantly improved in both BV-2 murine microglia (4A) and  in differentiated human 
neuroblastoma SH-SY5Y (4B) Data expressed as mean ± standard error (n=4). Comparisons are 


















Figure 5 Hydrogen peroxide induced caspase 9 protease activity is decreased in murine 
microglia (BV-2) and differentiated human neuroblastoma. Urolithins prevent the onset of 
intrinsic pathway apoptotic events by diminishing caspase 9 activity after incubating with BV-2 




 exposure for 6 
hours. Data expressed as mean ± standard error (n=4). Comparisons are made using H2O2 where  








Figure 6 Hydrogen peroxide induced caspase 3/7 release is abrogated in murine microglia (BV-2) 
and human neurons. 
Urolithins maintain cell viability and prevent the release of caspase 3/7 after incubating with BV-




 exposure for 6 hours. Data 
expressed as mean ± standard error (n=4). Comparisons are made using H2O2 where  P<0.05 * , 





















Figure 7 Pomegranate extract (PE) mitigates release of pro-inflammatory cytokines in 
hippocampi of transgenic mice fed PE.  Administration of PE to transgenic R1.40 AD mice at 200 
mg/kg appeared to show a decreasing trend in TNFα(A), IL-6  (B), COX-2 (C), and  IL-1 (D) 
expressed within the hippocampus. Comparisons are made using control diet fed mice where P< 
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Alzheimer’s disease (AD); amyloid-beta (Aβ); phenolic-enriched maple syrup extract (MSX); 
Thioflavin T (ThT); transmission electron microscopy (TEM); circular dichroism (CD); dynamic 
light scattering (DLS); amyloid peptide 1-42 (Aβ1-42); 2’,7’-dichlorofluorescin diacetate (DCFDA); 
lipopolysaccharide (LPS); resveratrol (RESV); Dulbecco's modified eagle medium: nutrient 
mixture F-12 (DMEM/F12); fetal bovine serum (FBS); dimethyl sulfoxide (DMSO); [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT); CellTiter-Glo (CTG); reactive 
oxygen species (ROS); nitric oxide species (NOS); nitric oxide (NO); interleukin-6 (IL-6); 
prostaglandin E2 (PGE2); tumor necrosis factor α (TNFα); enzyme linked immunosorbent assay 






Published data supports the neuroprotective effects of several phenolic-containing natural 
products, including certain fruit, berries, spices, nuts, green tea, and olive oil. However, limited 
data are available for phenolic-containing plant-derived natural sweeteners including maple 
syrup. Herein, we investigated the neuroprotective effects of a chemically standardized 
phenolic-enriched maple syrup extract (MSX) using a combination of biophysical, in vitro, and in 
vivo studies. Based on biophysical data (Thioflavin T assay, transmission electron microscopy, 
circular dichroism, dynamic light scattering, and zeta potential), MSX reduced amyloid β1-42 
peptide (Aβ1-42) fibrillation in a concentration-dependent manner (50-500 μg/mL) with similar 
effects as the neuroprotective polyphenol, resveratrol, at its highest test concentration (63.5% 
at 500 μg/mL vs. 77.3% at 50 μg/mL, respectively).   MSX (100 μg/mL) decreased H2O2-induced 
oxidative stress (16.1% decrease in ROS levels compared to control), and down-regulated the 
production of lipopolysaccharide (LPS)-stimulated inflammatory markers (22.1, 19.9, 74.8, and 
87.6% decrease in NOS, IL-6, PGE2, and TNFα levels, respectively, compared to control) in 
murine BV-2 microglial cells. Moreover, in a non-contact co-culture cell model, differentiated 
human SH-SY5Y neuronal cells were exposed to conditioned media from BV-2 cells treated with 
MSX (100 μg/mL) and LPS or LPS alone. MSX-BV-2 media increased SH-SY5Y cell viability by 
13.8% compared to media collected from LPS-BV-2 treated cells. Also, MSX (10 μg/mL) showed 
protective effects against Aβ1-42 induced neurotoxicity and paralysis in Caenorhabditis elegans in 
vivo. These data support the potential neuroprotective effects of MSX warranting further 
studies on this natural product. 
Keywords Maple syrup phenolics; neuroprotective; neuroinflammation; amyloid β1-42; 





Microglia cells are resident immune cells in the central nervous system which can be 
activated by abnormalities including oxidative and inflammatory stresses [1]. Chronic activation 
of microglia cells leads to the production of pro-inflammatory cytokines including nitric oxide 
synthase (NOS), interleukins, prostaglandins (PGs), and tumor necrosis factor α (TNFα) [2]. These 
neurotoxic inflammatory factors result in massive neuronal cell death and are linked to several 
neurodegenerative diseases including Alzheimer’s disease (AD), a progressive 
neurodegenerative disease [3]. AD is the most common cause of dementia and will afflict 11% of 
the United States population over the age of 65 costing the nation $226 billion in 2015 alone [4]. 
It is estimated that by 2050, the worldwide incidence of AD will triple unless innovative 
strategies, including dietary intervention, are implemented in addition to lifestyle changes and 
chronic disease management [5].  
The extensive neuronal loss that leads to functional and memory impairments in AD 
patients has been attributed to the proteotoxicity of extracellular amyloid-beta (Aβ) plaques and 
intracellular tau neurofibrillary tangles [6, 7]. Several pharmacological therapies focus on 
interrupting the underlying pathogenesis of AD in the brain [8]. While a common target is Aβ 
plaques, these approaches have largely been unsuccessful due to limitations in current scientific 




Therefore, there is a critical need to discover new therapeutic approaches to manage AD, 
especially since several drugs currently in clinical evaluation have been associated with severe 
side effects in patients [9]. Consequently, similar to several other chronic human diseases, the 
integration of natural products as part of a non-toxic dietary intervention strategy holds great 
promise for AD prevention [10].  This is due, in part, to the multi-mechanistic modes of action 
exerted by natural compounds, whereby, they could potentially prevent and/or delay the 
deleterious effects of oxidative stress, neuroinflammation, proteotoxicity, and other factors 
implicated in the pathogenesis of neurodegenerative diseases. 
Published data suggest that several phenolic-rich plant foods including certain fruits, 
berries, spices, nuts, green tea, and olive oil may show promise for AD prevention [10]. Phenolic 
compounds include a chemically diverse group of secondary metabolites containing a phenolic 
moiety which are prevalent in plant foods and their derived products.  Indeed, dietary plant 
extracts and their purified phenolic constituents such as resveratrol (from grape and red wine) 
[10], anthocyanins (from berries) [11], curcumin (from turmeric spice) [12], oleocanthal (from 
olive oil) [13], and catechin (from grape seed) [14], have been studied extensively for their 
biological effects against AD.  Several studies have noted that the biological activities of these 
single purified molecules are potentiated by synergistic, additive, and/or complementary effects 
of multiple (minor) constituents present in their respective phenolic-enriched ‘whole’ plant 




Thus, chemically standardized botanical extracts, delivered in food, supplement, and 
pharmaceutical matrices, hold great promise for the prevention of neurodegenerative diseases 
in future human clinical studies.  
Maple syrup is a plant-derived natural sweetener obtained by boiling the sap collected 
primarily from the sugar maple (Acer saccharum) species. Apart from its predominant 
constituent which is sucrose, maple syrup also contains oligosaccharides, amino acids, organic 
acids, vitamins, minerals, and phytohormones [16]. In addition, a large number of natural 
phenolic compounds originally present in the xylem sap of the sugar maple plant survive the 
boiling process and persist in maple syrup [16-19]. However, despite the wide consumption of 
maple syrup worldwide, and knowledge that it contains a diverse array of phenolic constituents 
(over fifty phenolics belonging to lignan, stilbene, flavonoid, coumarin, and phenolic acid sub-
classes have been isolated and identified from maple syrup) [17-19, 22], studies evaluating their 
health promoting effects are very limited.  Moreover, based on our knowledge to date, few 
studies have been conducted to evaluate the neuroprotective effects of this natural sweetener 
[20, 21]. In one of those studies, a phenolic-enriched maple syrup extract was shown to 
decrease oligomerization and aggregation of both Aβ1-42 and tau peptides, which are proteins 
involved in AD pathogenesis [20].  In light of the aforementioned factors, and given the paucity 
of data on the neuroprotective effects of natural plant-derived sweeteners, including maple 
syrup, we designed the current study. 
Our group has previously reported on the chemical standardization of a food grade 
phenolic-enriched maple syrup extract (named MSX) for nutraceutical applications [22]. This 
extract contains the natural phenolic constituents, as well as other substances (amino acids, 
organic acids, minerals, and oligosaccharides) present in the whole maple syrup food but with 




studies (in Sprague-Dawley rats) [22]. Notably, MSX shows anti-inflammatory effects (based on 
in vitro studies in RAW264.7 macrophages) superior to any of its purified phenolic constituents 
alone [23].  Therefore, given the aforementioned factors about the additive and synergistic 
effects observed with ‘whole’ plant extracts [15], as well as the possibility of a 
nutraceutical/botanical supplement being utilized as a dietary intervention strategy in future 
human clinical studies, we have chosen to advance our studies on this natural product by 
evaluating MSX rather than any of its purified single constituents alone.    
Herein, we sought to evaluate the neuroprotective effects of MSX against AD using a 
combination of biophysical (Thioflavin T assay, transmission electron microscopy, circular 
dichroism, dynamic light scattering, and zeta potential), in vitro (in murine BV-2 microglial, and 
human SY-SY5Y neuronal cells) and in vivo (in Caenorhabditis elegans) studies.  This is the first 
study to evaluate the effects of maple syrup constituents on markers of oxidative and 
inflammatory stresses in brain cells and its potential to delay Aβ1-42 induced neurotoxicity and 
paralysis in an in vivo AD model. 
 
Materials and Methods 
Chemicals 
Human amyloid peptide 1-42 (Aβ1-42) was purchased from AnaSpec (Fremont, CA, USA). 
Resveratrol (RESV), Folin-Ciocalteu reagent, thioflavin T (ThT), 2’,7’-dichlorofluorescin diacetate 
(DCFDA), lipopolysaccharide (LPS) and solvents were purchased from Sigma-Aldrich (St. Louis, 
MO, USA).  Uranyl acetate was purchased from Structure Probe Inc. (West Chester, PA, USA). 
ELISA kits for prostaglandin E2 (PGE2), and tumor necrosis factor α (TNFα) and interleukin-6 (IL-
6) were purchased from Cayman Chemical (Ann Arbor, MI, USA), and Abcam (Cambridge, MA, 





Phenolic-enriched maple syrup extract (MSX) 
The phenolic-enriched maple syrup extract (MSX), was prepared according to our previously 
reported methods [19, 22, 23].  The details of the MSX preparation and its chemical 
characterization (by HPLC-DAD analyses by comparison to authentic phenolic standards 
previously isolated from maple syrup), the structures of the compounds identified therein, and 
the carbohydrate (sucrose, glucose and fructose) and phenolic (by Folin-Ciocalteu assay based 
on gallic acid equivalents, GAEs) contents, are provided in the Supplementary Materials. 
 
Aβ1-42 thioflavin T (ThT) binding assay 
Aβ1-42 solutions were prepared following previously reported methods with minor modifications 
[24]. In brief, fibril formation was induced by incubating 50 µM Aβ1-42 solutions at 37 °C for 5 d. 
Treatment included MSX at varying concentrations (50, 100, 200 and 500 µg/mL) and the widely 
studied neuroprotective polyphenolic compound, resveratrol (RESV), used as the positive 
control (at 50 µg/mL). The ThT binding assay was used to evaluate Aβ1-42 fibrillation by adding 
ThT solution (200 µL) at a concentration of 10 µM to each sample (50 µL). The intrinsic 
fluorescence was immediately measured using a Spectra Max M2 spectrometer (Molecular 
Devices, Sunnyvale, CA, USA) at excitation and emission wavelengths of 450 and 483 nm, 
respectively. Percent inhibition (% inhibition) of each treatment was calculated based on 
arbitrary fluorescence (FU) by the following equation: % inhibition = [(FU of control − FU of 






Transmission electron microscope (TEM) analyses  
Aβ1-42 solutions for TEM analysis were prepared under the same conditions as the ThT binding 
assay. Aβ1-42 fibril formation was visualized by TEM as previously reported [25, 26]. The blank, 
control, and MSX (500 µg/mL) treated samples (5 µL each) were placed onto a 200 mesh carbon-
coated copper TEM grid (Ted Pella Inc., Redding, CA, USA) for 2 min. The excess fluid was 
removed by filter paper and 5% uranyl acetate (10 µL) was placed onto the grid for 2 min. Aβ1-42 
fibril formation was imaged using a Joel Corp. (Peabody, MA, USA) JEM 2100 TEM with a LaB6 
illumination filament operating at 200 kV.  
 
Circular dichroism (CD) analyses 
The change in the secondary structure of Aβ solutions were measured using a Jasco J-1100 CD 
spectropolarimeter (Jasco, Tokyo, Japan). Analyzed samples included 50 µM native Aβ1-42 
solution (non-incubated) and the aforementioned fibril-enriched Aβ solutions. CD 
measurements were carried out in the far-ultraviolet region from 190-260 nm using a quartz 
cuvette with a path length of 0.1 cm. The bandwidth was set at 1 nm for each run and 5 
repetitive scans were obtained. The Selcon 3 method was applied to calculate the secondary 






Dynamic light scattering (DLS) and zeta potential measurement 
The size of Aβ1-42 aggregates and zeta potential were measured with a Zetasizer Nano-ZS90 
(Malvern, Worcestershire, UK) as previously reported for the analyses of amyloid fibril 
formation [27]. Test samples included: 1) 50 µM freshly prepared Aβ1-42, 2) 50 µM Aβ1-42 
aggregated at 37 °C for 5 d and, 3) 50 µM aggregated Aβ1-42 co-treated with MSX (500 µg/mL) for 
5 d. Each measurement represents the average of three independent experiments and 100 
consecutive runs were obtained for each sample at an operating temperature of 25 °C. 
 
Cell culture 
The BV-2 murine microglial cells were a gift from Dr. Grace Y. Sun (University of Missouri at 
Columbia, MO, USA) and the SH-SY5Y (human neuroblastoma) cells were obtained from the 
American Type Culture Collection (ATCC). Cell lines were maintained using high glucose (4.5 g/L) 
DMEM/F12 (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% heat 
inactivated FBS (Life Technologies, Gaithersburg, MD, USA), 1% P/S (100 U/ml penicillin, 100 
μg/ml streptomycin) (Life Technologies, Gaithersburg, MD, USA) and incubated in 5% CO2 at 
37°C. After reaching a confluency of 85%, the SH-SY5Y cells were differentiated for 7 d using all-
trans retinoic acid (10 μM) while changing media every 48 h to ensure proper neurite growth 
and cell morphology. All samples were dissolved in DMSO (Sigma Aldrich, St. Louis, MO, USA) to 
yield a 10 mg/mL stock solution. Samples were further diluted to yield solutions with a final 






Measurement of cell viabilities    
Cell viabilities of BV-2 and SH-SY5Y cells were evaluated using the MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] colorimetric assay [28] and CellTiter-Glo 2.0 (CTG 2.0) one 
step assay (Promega Fitchburg, WI, USA), respectively. Briefly, in the MTT assay, BV-2 cells were 
seeded into 48-well plates at a density of 104 cells/well in DMEM. After 24 h, the cells were 
treated with MSX (50 or 100 μg/mL) for 48 h. At the end of the treatment, the cell viability was 
measured by using cell-counting kit 8 reagent (Dojindo Molecular Technologies, Rockville, MD, 
USA), according to the manufacturer's instructions. In the CTG 2.0 assay, SH-SY5Y cells were 
seeded at 105 cells/mL to yield 80-85% confluency in a standard white walled clear bottom 96-
well plate after 24 h initial incubation.  Following a secondary incubation period (24 h), CTG 2.0 
was added in a 1:1 ratio with the existing media in the wells and mixed for 2 min on an orbital 
shaker prior to luminescence measurement using the Spectramax M2 (Molecular Devices 
Sunyvale, CA, USA).  
 
Measurement of levels of reactive oxygen species (ROS)  
BV-2 cells were seeded into 48-well plates at a density of 104 cells/well in DMEM. After 24 h, the 
cells were pretreated with MSX (50 or 100 μg/mL) or the positive control, resveratrol (RESV; 5 
μg/mL) for 24 h. Then, the medium was replaced with DMEM containing 20 µM DCFDA for 20 
min. The cells were washed with phosphate buffered saline and incubated with H2O2 at a non-
toxic concentration (3.0 μg/mL) for 1 h. The fluorescence signal was read at excitation and 
emission wavelengths of 485 and 525 nm, respectively, using a Spectra Max M2 spectrometer 





Measurement of nitric oxide species (NOS) levels by Griess assay 
BV-2 microglial cells in 24-well plates (n = 4) at 85% confluency (105 cells/well) were serum-
starved for 4 h prior to the treatments. Then the cells were incubated with MSX (50 or 100 
μg/mL) or the positive control, resveratrol (RESV; 5 μg/mL) for 1 h before lipopolysaccharide 
(LPS) was added. After 23 h incubation, the cell culture media were collected and centrifuged. 
The supernatants were measured for total nitric oxide (NO) levels using the Griess assay kit 
(Promega, Fitchburg, WI, USA) as previously reported [23]. Sodium nitrite, at different dilutions, 
was used to generate a standard curve which was used to calculate nitrite concentrations. 
 
Measurements of IL-6, PGE2, and TNFα levels 
Supernatants collected from the NO experiments above were collected and assayed for 
inflammatory cytokines including interleukin-6 (IL-6), prostaglandin E2 (PGE2) and tumor 
necrosis factor α (TNFα). Quantification of PGE2 and TNFα were measured using enzyme linked 
immunosorbent assay (ELISA) kits based on the respective manufacturer protocols.  
 
Non-contact co-culture model with BV-2 and SH-SY5Y cells 
BV-2 and SH-SY5Y cells were co-cultured as previously reported [29-31].  Briefly, BV-2 and 
differentiated SH-SY5Y cells (both cell lines at a density of 105 cells/mL) were plated in 12-well 




The BV-2 cells were then exposed to MSX (50 and 100 μg/mL) or RESV (5 μg/mL; positive 
control) for 1 h prior to exposure to LPS (1 μg/mL) for a duration of 24 h of treatment.  
Conditioned media were then collected from the BV-2 cells and centrifuged at 18,000 rcf for 5 
min at 4°C.  The media from the SH-SY5Y cells was removed and replaced with the centrifuged 
conditioned media from the BV-2 cells and left to incubate for 24 h after which they were 
subjected to the CTG 2.0 assay to assess cell viability.   
 
Transgenic Caenorhabditis elegans in vivo assay 
The C. elegans nematode assay was carried out as previously reported by our group [24]. Briefly, 
the transgenic C. elegans strain CL4176, developed to express human amyloid β1-42 in the muscle 
tissue in response to heat shock, were obtained from the Caenorhabditis Genetics Center (CGC) 
(University of Minnesota, Minneapolis, MN, USA). Worms were grown and maintained at 16 oC 
on 60 mm culture plates with Nematode Growth Medium (NGM). Media was poured aseptically 
into culture plates (10 mL for 60 mm) using a peristaltic pump and allowed to solidify for 36 h. 
NGM culture plates were then inoculated with 50 μL of Escherichia coli OP50 (CGC, University of 
Minnesota, Minneapolis, MN, USA) overnight cultures and incubated for 8 h at 37 oC. The C. 
elegans were maintained by picking 2-3 young adult worms onto freshly inoculated NGM plates 
every 4-7 d. MSX was dissolved in S-basal buffer and methanol solution (1:1; v/v) and further 
diluted in S-basal buffer to a yield a final concentration of 1 mg/mL which served as the stock 
solution. The MSX stock solution was added directly to the NGM media for a final treatment 





  Upon development of the eggs to the L3 larval stage, the incubation temperature of the plates 
was increased from 16 to 25 °C to induce the expression of Aβ1-42. Mobility scoring was 
conducted beginning at 20 h after the temperature increase and continued in 2 h increments 
until all of the worms were paralyzed. Failure to respond to touch (prodding with a worm pick) 
and, absence of pharyngeal pumping, were used to score paralyzed/dead worms.  
 
Statistical analyses 
Data are presented as mean ± standard deviation of at least 3 separate experiments. For the ThT 
assay, statistical analysis was conducted by one-way factorial ANOVA with Tukey-Kramer post 
hoc comparisons. Cellular assay data were expressed as means ± standard errors. P values were 
generated using ANOVA followed by Dunnett’s test for multiple comparisons of group means. 
For the in vivo C. elegans assay, the Kaplan-Meier method was used to compare the lifespan 
survival curves and the survival differences were tested for statistical significance using the Log 
rank test (Mantel Cox). Significance for all tests was defined as: p≤0.05 (*), p≤0.01 (**), p≤0.001 
(***), and p≤0.0001 (****). GraphPad Prism software 6.0 (GraphPad Software, Inc., San Diego, 





Results and Discussion 
Chemical characterization of phenolic-enriched maple syrup extract (MSX)  
MSX is a chemically standardized food grade phenolic-enriched maple syrup extract, previously 
developed by our group for nutraceutical applications, with established safety and tolerability 
data in animals [22].  For the present study, MSX was prepared in our laboratory based on 
methods previously reported by our group (details provided in Supplementary Materials). 
Our group has previously isolated and identified (using NMR and mass spectrometry) 
over fifty phenolic compounds from maple syrup [19, 22, 23]. Therefore, through comparison of 
HPLC-DAD retention times with these chemical marker standards, as shown in Fig. 1, a total of 
thirty-seven compounds (chemical structures provided in Fig. S2 in the Supplementary 
Materials) were identified in MSX. As expected, the majority of the compounds in MSX are 
phenolic compounds, belonging to lignan, coumarin, phenolic acid, and stilbene sub-classes.  
The phenolic content of MSX used in the present study was determined as 24.0% (based 
on gallic acid equivalents, GAEs). In addition, it had a sucrose content of ca. 10.0% as compared 
to pure maple syrup which was 63%. The levels of fructose and glucose in MSX were < 0.1%. We 
next sought to evaluate the neuroprotective effects of MSX using a combination of biophysical 
(Thioflavin T assay, transmission electron microscopy, circular dichroism, dynamic light 
scattering and zeta potential), in vitro (murine BV-2 microglial, and human SH-SY5Y cells) and in 






MSX inhibits Aβ fibrillation 
Aβ deposition in brain leads to the formation of senile plaques and causes neurotoxicity in AD 
patients. During the progression of AD, soluble unstructured Aβ peptides gradually reassemble 
to insoluble Aβ fibrils, a structure enriched in β-sheet confirmation. Therefore, MSX was 
evaluated for its inhibitory effects on the formation of Aβ1-42 fibril structures using a combination 
of biophysical methods. Aβ1-42 fibrillation was first quantified by the fluorescence based ThT 
binding assay (Fig. 2A) and the morphology of the fibrils was visualized by TEM (Fig. 2B). The β-
sheet contents were measured by circular dichroism (CD) studies (Fig. 3). The size and zeta 
potential of Aβ1-42 aggregates were measured by zetasizer (Table 1).  
As shown in Fig. 2A, the control generated the highest binding level in the ThT assay 
indicating that the control group had the highest level of Aβ1-42 fibrillation.  The Aβ1-42 fibrillation 
level significantly decreased in all of the treatment samples including the different 
concentrations of MSX (from 50-500 μg/mL) and the neuroprotective polyphenolic compound, 




The data generated in the current study for RESV (50 µg/mL, inhibition = 77.3%, p≤0.001) is in 
agreement with previously published data [32]. Similarly, the MSX treated solutions showed a 
concentration-dependent effect at 500, 250, 100 and 50 µg/mL, reducing Aβ fibrillation by 63.5, 
55.9, 54.9 and 18.9%, respectively. Therefore, the ThT assay data suggested that both MSX and 
RESV significantly inhibited Aβ fibrillation. Also, it should be noted that the lowest test 
concentration of MSX (50 µg/mL) significantly inhibited the formation of Aβ1-42 fibrils (p≤0.05).   
Our findings from the ThT assay were further confirmed by the TEM analyses. As shown 
in Fig. 2B, the control Aβ1-42 sample generated morphology of aggregates typically seen in the 
fibrillation process of Aβ1-42 [25, 26]. In contrast, the Aβ1-42 co-treated with MSX (500 µg/mL) 
sample showed a different morphology compared to the control. The overall fibrils in the MSX 
treated solution were significantly less dense but more amorphous, indicating that the 
formation of highly ordered Aβ fibrils was reduced by MSX.  
Next, we measured the β-sheet contents in Aβ1-42 solutions using CD spectroscopy 
(shown in Fig. 3 and Table 1). Compared to native non-aggregated Aβ1-42, all of the incubated 
samples displayed a signature dip at 220 nm, indicating the formation of β-sheets structures 
[33]. However, in the MSX treated sample (500 µg/mL), the conformational changes of the β-
sheets were 10% lower than that of control (49.6 vs. 59.6%). A similar trend was observed for 




Aβ1-42 fibrillation can cause the formation of aggregates which can be measured by 
dynamic light scattering (DLS) [27]. Based on DLS measurements (shown in Table 1), no 
measurable aggregates were observed in native freshly prepared Aβ1-42. In contrast, after 
incubation at 37 °C, Aβ1-42 yielded aggregates with particle size of 317.9 nm and a dominant 
content of 86.4% which were reduced to 39.84 nm and 77%, respectively, by MSX (500 µg/mL).  
As previously reported, the zeta potential of Aβ1-42 shifts to a more negative value as aggregation 
progresses [27]. Our data is in agreement with these observations [27] wherein we observed a 
significant decrease in zeta potential values from -4.58 mV for freshly prepared Aβ1-42 to -22.4 
mV for aggregated Aβ1-42.  However, the MSX treated Aβ1-42, generated an increase in zeta 
potential value of -17.6 mV, indicating that the aggregation process was less extensive than the 
control. 
Taken together, the biophysical data from the ThT assay, TEM analyses, CD experiment, 
DLS, and zeta potential measurements suggested that the MSX treatments effectively inhibited 
Aβ1-42 structural transformation from soluble non-toxic peptides to insoluble neuro-toxic fibrils. 
These data are in agreement with the previous report for a phenolic-enriched maple syrup 
extract [20].  However, to date, no previous studies have been conducted to evaluate the 
neuroprotective effects of maple syrup in brain cells or in an in vivo AD model; therefore, we 





MSX protects murine BV-2 microglia against H2O2-induced oxidative stresses in vitro 
Microglia cells are resident innate immune cells in the central nervous system with a similar 
functional role as macrophages. An important cellular response in neurodegenerative diseases 
pathogenesis is microglial activation. Moreover, the over-activation of microglia can lead to the 
release of a variety of pro-inflammatory mediators which are potentially neurotoxic.  This 
activation process is often promoted by cellular oxidative stress factors including reactive 
oxygen species (ROS) and thus, the reduction of ROS levels alleviates microglial activation and 
related neuronal disorders [34].  Therefore, MSX was evaluated (at non-toxic concentrations, 
ranging from 10 to 100 μg/mL based on the MTT assay, as shown in Fig. 4A) for its effects on 
H2O2 (3.0 μg/mL) induced ROS production in murine BV-2 microglia cells.  As shown in Fig. 4B, 
MSX decreased H2O2-induced ROS production in BV-2 cells. At concentrations of 50 and 100 
μg/mL, MSX reduced H2O2-induced ROS production by 9.9 and 16.1%, respectively. The positive 
control, RESV, decreased H2O2-induced ROS levels by 66.2% at a concentration of 5 μg/mL, 





MSX protects murine BV-2 microglia against LPS-induced inflammatory stresses in vitro 
Our group has previously shown that MSX reduced pro-inflammatory cytokines in RAW264.7 
murine macrophages [23] but to date, these effects have not been investigated in brain cells. 
Herein, we evaluated whether MSX could reduce levels of biomarkers for neuronal 
inflammation, induced by LPS, in BV-2 cells. Indeed, the LPS treated cells produced higher NO 
levels compared to untreated cells (51.9 vs 9.2 μM).  As shown in Fig. 5A, MSX inhibited NO 
production. At 50 and 100 μg/mL, MSX decreased NO production by 10.0 and 22.1%, 
respectively. Similar to previously reported data [34], RESV (5 μg/mL), reduced LPS-induced NO 
production by 23%.  
Next, MSX was further evaluated for its effects on inflammatory cytokines, IL-6, PGE2 
and TNFα, in the BV-2 cells. As shown in Fig. 2A, after incubation of the BV-2 microglial cells with 
LPS, MSX (100 μg/mL) significantly (by 19.9%) reduced IL-6 levels as compared to the LPS 
treated control cells. However, the IL-6 production was not significantly (4.2 %) reduced by 
treatment of MSX at the lower concentration of 50 μg/mL.  The levels of PGE2 were reduced by 
52.9 and 74.8%, after treatment with 50 and 100 μg/mL MSX, respectively, compared to LPS 
treated control cells,  In comparison, the positive control, RESV (5 μg/mL), reduced PGE2 levels 
by 22.5% which was similar to previously reported data [34] (Fig. 5C).  Similarly, the levels of 
TNFα were down-regulated by treatment of BV-2 cells with MSX (Fig. 5D) by 75.2 and 87.6%, 
after treatment with 50 and 100 μg/mL MSX, respectively, compared to the LPS treated cells.  
The positive control, RESV (5 μg/mL), decreased TNFα levels by 31.4% similar to previously 






MSX reduces cytotoxicity of human SH-SY5Y neuronal cells after exposure to murine BV-2 
microglia conditioned media 
Co-culture systems have been employed to investigate the impact of microglia and its 
inflammatory mediators on the cell death of neurons [29-31, 35]. Therefore, we used a non-
contact cell culture model (using conditioned media) to evaluate the protective effects of MSX 
against neurotoxicity (induced by inflammatory biomarkers released by LPS-stimulated BV-2 
microglia) of differentiated human SH-SY5Y neuronal cells as previously reported [30, 31]. As 
shown in Fig. 6, media from BV-2 cells (treated with LPS alone) significantly decreased (15.0%) 
the cell viability of differentiated SH-SY5Y neuronal cells. On the contrary, the conditioned 
media from BV-2 cells treated with MSX (at 100 and 50 μg/mL) reduced SH-SY5Y neuronal cell 
death by 17.7 and 13.8%, respectively.  The positive control, RESV (5 μg/mL), decreased the SH-
SY5Y neuronal cell death by 30.5%.   This observation indicated that MSX was able to ameliorate 
microglia-mediated neuronal cell death possibly by decreasing the production of inflammatory 





MSX protects Aβ1-42 induced neurotoxicity and paralysis in Caenorhabditis elegans in vivo 
We next evaluated the effects of MSX in an established C. elegans in vivo model of AD 
[24]. The mobility curves for the C. elegans CL4176 strain after the Aβ1-42 induction of muscular 
paralysis at 25 °C are shown in Fig. 6. Compared to the control worms (Fig. 7A), treatment with 
10 μg/mL MSX did not have any significant effect on the median survival/mobility in C. elegans 
post induction of Aβ1-42 induced neurotoxicity and paralysis. However, MSX treatment (Fig. 7B) 
significantly increased the maximum survival/mobility by 3.0% and decreased the mean 
survival/mobility post induction of Aβ1-42 induced neurotoxicity and paralysis by 10.4% (as shown 
in Table 2).  
Mitochondrial dysfunction, inflammation, oxidative stress, and activation of apoptotic 
signaling due to intra- and extracellular accumulation of misfolded or damaged proteins has 
been linked to the etiopathology of neurodegenerative diseases, including AD [36, 37]. 
Therefore, therapies that specifically target mediators of proteotoxicity and inflammation may 
be more successful in ameliorating neurodegenerative processes [38]. The transgenic AD model 
of C. elegans used in our study specifically measures the intracellular aggregation of the Aβ1-42 
peptide in muscle tissues and permits investigation of inflammatory and proteotoxicity 
contributors of Aβ1-42 peptide aggregation and subsequent neuromuscular paralysis [24, 39, 40].  
In response to treatment with MSX, the heat-shock induced aggregation of Aβ1-42 peptide and 




These results corroborated our observations from the biophysical and in vitro studies wherein 
MSX reduced Aβ1-42 fibrillation, oxidative stress, and inflammatory cytokines.  It is possible that 
the reduced proteotoxicity in C. elegans in response to MSX could be due to the presence of 
certain bioactive compounds that interacts with amyloidogenic proteins to prevent their 
oligomerization (and thus aggregation) [41].  However further studies would be required to 
confirm this. Overall, the current study with MSX support studies done with other natural 
products including coffee bean extract [42], Ginkgo biloba [41], curcumin, and several tropical 
fruit extracts [39, 40], suggesting similar mechanism/s for reducing Aβ1-42 aggregation by 






In summary, using a combination of biophysical, in vitro, and in vivo studies, a phenolic-
enriched extract of maple syrup (MSX) was shown to reduce Aβ1-42 fibrillation and decrease 
oxidative and inflammatory stresses in murine BV-2 microglial cells and SHSY-5Y neuronal cells.  
Furthermore, MSX imparted protective effects on Aβ1-42 aggregation induced neurotoxicity and 
paralysis in C. elegans. However, further in vivo studies to confirm the neuroprotective effects of 
MSX, and to predict a human equivalent consumption dose, are necessary given that the current 
data does not account for important physiological considerations such as bioavailability and 
metabolism.  Nevertheless, these findings add to recently published data supporting the 
potential neuroprotective effects of maple syrup [20, 21], warranting further studies on this 
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Figures and captions 
Fig.1 HPLC-DAD chromatogram of a phenolic-enriched maple syrup extract (MSX) showing 37 
compounds identified as follows: (1) 4-hydroxy-2-(hydroxymethyl)-5-methyl-3(2H)-
furanone, (2) 3,4-dihydro-5-(hydroxymethyl)pyran-2-one, (3) 5-(hydroxymethyl)furfural, 
(4) 2-hydroxy-3,4-dihydroxyacetophenone, (5) 4-(hydroxymethyl)-1,2-benzenediol, (6) 
catechol, (7) C-veratroylglycol, (8) threo,threo-1-[4-(2-hydroxy-2-(4-hydroxy-3-
methoxyphenyl)-1-(hydroxymethyl)ethoxy)-3-methoxyphenyl]-1,2,3-propanetriol, (9) 
2,3-dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)-1-propanone, (10) 4-acetylcatechol, 
(11) tyrosol, (12) catechaldehyde, (13) 1,2-diguaiacyl-1,3-propanediol, (14) 3’,5’-
dimethoxy-4’-hydroxy-2-hydroxyacetophenone, (15) leptolepisol D, (16) 3,4-dihydroxy-
2-methylbenzadehyde, (17) vanillin, (18) fraxetin, (19) syringaldehyde, (20) syringenin, 
(21) scopoletin, (22) threo-guaiacylglycerol-β-O-4’-dihydroconiferyl alcohol, (23) erythro-
guaiacylglycerol-β-O-4’-dihydroconiferyl alcohol, (24) 5-(3’’,4’’-dimethoxyphenyl)-3-
hydroxy-3-(4’-hydroxy-3’-methoxybenzyl)-4-(hydroxymethyl) dihydrofuran-2-one, (25) 
1-(2,3,4-trihydroxy-5-methylphenyl)ethanone, (26) erythro-1-(4-hydroxy-3-
methoxyphenyl)-2-[4-(3-hydroxypropyl)-2,6-dimethoxyphenoxy]-1,3-propanediol, (27) 
icariside E4, (28) 3’,4’,5’-trihydroxyacetophenone, (29) dehydroconiferyl alcohol, (30) 








methoxyphenyl)-1,3-propanediol, (35) 4,4’-dihydroxy-3,3’,5,5’-tetramethoxystilbene, 
(36) 4,4’-dihydroxy-3,3’,5’-trimethoxystilbene, and (37) (E)-3,3’-dimethoxy-4,4’-
dihydroxystilbene. 
Fig. 2 (A) ThT binding assay showing the levels of Aβ1-42 aggregation treated with different 
concentrations of MSX (50-500 µg/mL) or positive control resveratrol (RESV; at 50 
µg/mL); (B) TEM analyses of Aβ1-42 solution freshly mixed with 500 µg/mL MSX without 
incubation (left), Aβ1-42 solution incubated for 5 d (middle) and Aβ1-42 solution co-treated 
with 500 µg/mL MSX then incubated for 5 d (right).  
Fig. 3 Circular dichroism (CD) measurement of native Aβ, aggregated Aβ, and Aβ co-treated with 
MSX (500 ug/mL). 
Fig.4  MSX reduced H2O2-induced oxidative stress in BV-2 murine microglial cells. (B) BV-2 cells 
were pretreated with MSX (50 or 100 μg/mL) for 24 h followed by 1 h of H2O2 (3 μg/mL) 





Fig. 5 BV-2 cells pretreated with MSX (50 or 100 μg/mL) for 1 h followed by exposure to LPS (1 
μg/mL) for 24 h. The treated cell culture media were used to assay the amount of NOS 
(A), IL-6 (B), PGE2 (C), and TNFα (D) production. Resveratrol (RESV, at 5 μg/mL) served as 
the positive control for all the assays. Data are presented as means ± SDs of three 
independent experiments.  
Fig. 6 MSX reduced murine BV-2 microglia-mediated neurotoxicity of human SH-SY5Y neuron 
cells. BV-2 cells were treated with MSX (50 and 100 μg/mL) or resveratrol (RESV, 5 
μg/mL; positive control) for 1 h prior to exposure to LPS (1 μg/mL) for 24 h. The 
conditioned media from the BV-2 were collected and added to SH-SY5Y cells. After 
incubation for 24 h, cell viability of  SH-SY5Y cells were measured by the CTG 2.0 assay.  
All data points were compared to the LPS column. 
Fig. 7 Mobility curves of transgenic (CL4176) C. elegans 20 h post Aβ1-42 induction of muscular 
paralysis at 25 °C. Kaplan-Meier mobility plots of C. elegans worms fed on (A) Control 







































Table 1. Measurement of zeta potential, particle size distribution, and β-sheet content of native 
Aβ1-42, aggregated Aβ1-42 and MSX (500 µg/mL) treated Aβ1-42. (n.d. = not detected) .  
 
Native Aβ1-42 Aggregated Aβ1-42 MSX (500 µg/mL) 
Zeta Potential (mV) -4.58 -22.4 -17.6 










Table 2. Survival (mean, median, and maximum) of (CL4176) C. elegans worms treated with MSX 
(10 μg/mL) post Aβ1-42 induction of muscular paralysis at 25 oC. [* p< 0.05; Log rank test (Mantel 
Cox)]. 




Survival time (h) 
Mean Median Maximum 
Control (n>1000) 29.60 26.00 30.27 
MSX (n>1000) 26.50* 26.00 31.20* 
    
 
 
















The modulation of inflammation and the targets critical to the pathogenesis of 
neurodegenerative and metabolic diseases through the use of functional foods appears to be a 
somewhat distant reality. Manuscript 1 demonstrated that PE modulated hippocampal 
inflammation, reduced AD-associated genes (APP, GSK3β, and MAPT), reduced body, liver, and 
white adipose tissue weight while also improving hepatic metabolic function in diet-induced 
obese mice. Moreover, in manuscript 4 the BBB-permeable metabolites, urolithins, prevented 
reactive microgliosis and microglia mediated neuron death. 
MSX was thoroughly evaluated for similar immunomodulatory effects in vivo and in 
vitro. Manuscript 2 evaluated the anti-neuroinflammatory effects of MSX in a diet-induced 
obesity rodent model and more importantly, showed a potential for modulating leptin receptor 
signaling within the hippocampus. MSX also showed beneficial effects in preventing liver lipid 
accumulation and promoted lipid metabolism which prompted further investigation through a 
more robust study in manuscript 3. 
This larger study used a more compositionally realistic western-style diet which included 
the addition of fructose and glucose in drinking water. MSX surprisingly had the opposite effect 
than we hypothesized and exacerbated hepatic lipid metabolism and transport. One possible 
explanation aside from the detrimental effects of fructose consumption on liver lipid 
accumulation and function would be the stereospecific production of (+) EL over (-) EL. The 
current body of research suggests that the (+) and even racemic mixture may augment hepatic 
de novo lipogenesis. (-) SECO, (-) ED, and (-) EL potentiated the effects of a similar diet-induced 





Given that microbial transformation of ED to EL is stereospecific (i.e. (+) ED can only be 
converted to (+) EL), microbial dysbiosis due to HFD consumption with fructose, may promote 
the growth of unique bacteria capable of this ED to EL stereospecific transformation. 
Confirmation of which form of EL exists should be determined by LC-MS analysis of week 18 
sera. Additional studies involving only the biologically relevant entities are still needed to 
explore the toxicological effects of simultaneous high fat-high fructose consumption with the 
microbial metabolites of MSX.  
As with PE and the discovery of urolithins, the methodologies used to determine the 
biologically present microbial metabolites are needed to identify the active constituents of MSX. 
Fermentation studies using an artificial gut system with MSX incubated in human fecal innocula 
at varying pH conditions should be used to model the environment of the gut. The end result 
should produce microbial metabolites such as Enterolignans (ED and EL) and potentially new 
molecular entities. With these metabolites identified, passive and active permeability of these 
metabolites through the intestinal epithelial barrier and the blood brain barrier should be 
quantified to ascertain which compounds may enter hepatic circulation and the brain. With a 
more defined and biologically relevant pool of metabolites, mechanism of action studies 
involving the toll-like receptor 4 – NfKB pathway as well as the possible effects of astrocyte 
mediated leptin receptor signaling should be explored.  
Manuscript 5 demonstrated MSX significantly attenuated pro-inflammatory cytokines 
and pre-mature cell death in human monocytes, immortalized macrophages, immortalized 
neurons and even murine microglia. Future studies once more should screen for only the BBB 





While PE continues to be heavily researched for a number of disease states, MSX is still 
an interesting source of beneficial compounds and metabolites. Future studies involving MSX 
should focus on determining the bioactive and bioavailable metabolites present in mammals. 
Given the complexity of MSX, the stereospecific microbial conversion of EL represents just one 
possibility apart from the simple addition of fructose that could support our findings from the 
initial pilot study in manuscript 2 and the larger multi-dose study of manuscript 3.  In closing, 
this research will contribute to the ever growing body of research aimed at identifying and 
characterizing natural products with immunomodulatory activity. More importantly, this work 
underscores the importance of gut microbial metabolism as a significant source of beneficial and 
harmful metabolites capable of promoting or worsening health.  
